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Abstract
Polyesters have been used for many biomedical applications ranging from sutures to drug
delivery vehicles. However, their bulk degradation results in an accumulation of acidic
byproducts, which is detrimental to the human body. In order to circumvent this problem, as
well as to impart new properties and functions to polymers for biomedical applications,
poly(ester amide)s (PEAs) have been proposed as a different class of biodegradable
polymers. However, up to date, there exists no way to stimulate the degradation of these
polymers.
The Gillies research group has previously incorporated self-immolative spacers into
polymers and has been able to stimulate their degradation by adding the appropriate trigger.
The objective of this thesis was to incorporate amino acids capable of 1,5-cyclization into the
PEA backbone such that upon activation of the functional moiety, a 1,5-cyclization was
induced, leading to degradation of the PEA backbone. PEAs containing L-2,4-diaminobutyric
acid and DL-homocysteine were synthesized and their degradation was monitored in
solution, and in films. It was found that the polymers containing the self-immolative spacers
degraded faster than their controls under specific triggers (i.e. change in pH, reducing
conditions, UV light), thereby allowing polymer degradation to be accelerated under these
specific conditions.

Keywords
poly(ester amide), degradable polymer, self-immolative, pendant functional group, pH,
reducing conditions, UV light, cyclization.
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Chapter 1
Biodegradable and stimuli-responsive polymers for
biomedical applications
1.1 General introduction
Polymers that degrade under biological conditions have become a part of our daily lives.
Due to their biocompatibility and their structural properties they have found many uses
and have even achieved FDA approval in many cases. They have found applications in
areas such as packaging (both medical and commercial), 1,2 medical implants (such as
stents and internal fixation devices), 2 drug delivery, 2 and have even been used as
scaffolds for tissue engineering.1,2 Among the polymers used are the polyesters, whose
structures are shown (Figure 1.1).

Figure 1.1 Chemical structures of common polyesters.
Another class of polymers that has also emerged for biomedical applications is
poly(ester amide)s (PEAs) (Figure 1.2). These polymers, as well as other polymers which
are stimuli-responsive are also shown in Figure 1.2 and shall be of interest to this thesis.
Their advancements in the areas of drug delivery, tissue engineering, and biomedical
applications such as stents shall also be reviewed.
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Figure 1.2 Chemical structures of other biodegradable polymers.

1.2 Biomedical applications: Tissue engineering & drug
delivery
Tissue engineering is a multi-disciplinary field which aims to apply the principles of
engineering and the life sciences in order to develop biological materials that can restore,
maintain, or improve tissue functions. Its main focus is to overcome the lack of tissue
donors, while at the same time avoiding the immune response between host and guest. In
this process, cells are cultured onto a scaffold which is then placed in the non-functioning
part of the patient. In some cases, the culturing on the scaffold may be skipped altogether
such that the scaffold (or the scaffold containing cells), is placed in vivo directly and the
host’s body acts as a bioreactor to construct new tissues.1,2
Ideally, a scaffold should not only meet the bulk mechanical and structural
requirement of the target tissue; it should also enable molecular interactions with cells
that promote healing. To this end, synthetic polymers are viable candidates owing to their
material properties that are more flexible than those of natural materials. Their
mechanical and chemical properties may also be adjusted accordingly and the materials
are readily prepared and in some cases, inexpensive to produce.2
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Drug delivery is another application in which polymers may be utilized. The
hydrophobicity of some drugs hampers their ability to be administered and can result in
their rapid clearance from the body. Synthetic polymers not only increase the solubility of
drugs in water, but they also provide numerous advantages. Among them is the protection
of bioactive drugs from degradation by the host, protection of the host from the toxicity
of the drug thus increasing the therapeutic index of the drug, targeting of cells and
organs, delivery of drugs at a predetermined rate and avoiding the need for repeated
administrations. 3 Due to their ability to degrade over time, polyesters have found
applications as packaging, both medical and commercial.3,4,5

1.3 Polyesters for biomedical applications
Among the polymers that have been used most for biomedical applications are the poly
(hydroxyacid)s. These polymers have been chosen due to their ease of synthesis (Scheme
1.1), biocompatibility, and because their degradation byproducts are broken down into
water and carbon dioxide via the citric acid cycle.1,6,7 The polymers most commonly used
for biomedical applications are: PGA, PLA, PLGA, and PDLLA. As these polymers
contain hydrolytically labile ester linkages along their backbones, they are susceptible to
hydrolysis. Each has different rates of degradation due to their differing hydrophilicities
and solid state structures.

Scheme 1.1 Synthesis of polyester from a) glycolide (GA) b) racemic lactide (LA) c)
glycolide and lactide.
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As PGA is a highly crystalline polymer, it has a high tensile strength and low
solubility in organic solvents. As a result of its high crystallinity, it has excellent
mechanical properties which prompted its use as the bone internal fixation device,1
Biofix®. PGA was also one of the first polymers to be approved as a resorbable suture in
19691,5 under the trademark name DEXON®. This particular polymer has been known to
degrade in 6-12 months.
PLA is another polymer that has garnered much attention. Due to the monomer’s
optical activity, PLA comes in two forms: the D and L isomer, with the L isomer being
more prevalent. Like PGA it is also crystalline, which results in a high tensile strength
and a high modulus which makes it ideal for load-bearing devices such as orthopaedic
devices. It can also be made into a high strength fiber and as a result, was chosen as a
more effective suture over DEXON® in 1971. Recently, an injectable form of PLLA
(Sculptra®), has received FDA approval for the restoration or correction of facial fat loss
and lipoatrophy in patients suffering from the human immunodeficiency virus.1 Due to its
more hydrophobic nature (owing to its methyl group), PLA has a longer degradation time
and has been known to take 2-6 years to degrade.3,8 In contrast, stereoisomeric PDLLA
containing a mix of D and L monomers has been known to degrade in a period of 12-16
months, thereby highlighting the effect of stereochemistry on degradation.2,9 Other
factors that affect polyester degradation are Tg, crystallinity, MW, PDI, tacticity, as well
as the sequence of monomers.2,4,9,10,11 As a result, in order to maximize the degradation of
polyesters, various copolymers containing lactide and glycolide have been synthesized to
exploit the characteristics of each monomer.
Various mixtures of L-lactide and glycolide have been used over the years and it
has been found that the more lactide incorporated, the slower it degrades. As a
consequence, PLGAs have been known to degrade in a short period of 2-3 months,
upward to a year. A co-polymer containing 90% glycolide and 10% lactic acid has been
used for the development of a multifilament suture, Vicryl®. PANACRYL® is another
commercially available suture containing the same monomers, only with a higher lactide
ratio in order to decrease the degradation.1 PLGA also exhibit good cell adhesion and
proliferation, thereby making them an excellent candidates for tissue engineering. PLGAs
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have been used to synthesize the tissue engineered skin graft (Dermagraft®), using Vicryl
mesh® as the scaffolding structure; Vicryl mesh® was made from the PLGA co-polymer.1
Another application for this polymer and other polyesters is in the area of drug
eluting stents. Drug eluting stents have been accepted by interventional cardiologists over
bare metal stents due to their lower restenosis rate.12 In the last couple of years, the focus
has been shifted to stents that can not only release drugs, but also degrade over the
treatment period. This would be ideal in that it would omit another surgical step to
remove the stent from the patient. Among the candidates is the Conor stent which elutes
paclitaxel (Figure 1.3). In a 1700 patient study, it was found to not only have a greater
target vessel revascularization (TVR) than the commercially available Taxus stent, but it
was also found to have less major adverse cardiac events (MACE) as well.12 In a recent
follow up of a ten year study; it was found that the first fully bioabsorbable stent, known
as the Igaki-Tamai stent (made entirely out PLLA), had MACE rates similar to that of
bare metal stents.13

Figure 1.3 Paclitaxel (taxol).

1.4 Polyesters for drug delivery
Tumors that reside in the body need a tremendous amount of oxygen and nutrients in
order to sustain their growth. They release growth factors such as VEGF (vascular
endothelial growth factor) in order to facilitate the growth of new blood vessels. Unlike
regular blood vessels, these vessels contain cell junctions that are not as tight as normal
ones. As a result, anything that enters these vessels remains trapped therein.14 Many drug
delivery systems have taken advantage of this phenomenon (otherwise known as the
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enhanced permeation and retention effect; EPR for short), including those that contain
polyesters.
Of the ways to deliver a drug to the body, drug delivery using self-assemblies has
garnered much attention. The driving force behind these assemblies relies on the
hydrophobic and hydrophilic characteristics of block copolymers. When a polymer
containing a relatively hydrophobic block (such as polyester), is connected to a more
hydrophilic block such as (polyethylene glycol (PEG)) and is immersed in water, the
polymers arrange themselves such that the hydrophobic blocks minimize contact with
water. Of the various shapes formed, the spherical micelle shall be discussed herein; it is
also widely studied in the area of drug delivery (Figure 1.4).

Figure 1.4 Formation of a spherical micelle.

The hydrophobic core of the micelle provides an opportunity for hydrophobic
drugs such as doxorubicin (Figure 1.5), which would otherwise exhibit limited solubility
in the body to be delivered to their target. This in turn increases the bioavailability of the
drug, thereby increasing its efficacy. There have been various reports utilizing this drug
delivery type system.15-17
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Figure 1.5 Doxorubicin (DOX).
One of the major disadvantages to incorporating hydrophobic drugs in the core of
micelles is that they exhibit poor loadings and they release their drugs over a shorter
period of time. In order to circumvent this, Park and coworkers conjugated the terminal
hydroxyl group of the PLGA by first activating it with p-nitrophenyl chloroformate,
which was later used to conjugate doxorubicin (Scheme 1.2).15

Scheme 1.2 Synthetic route to DOX-PLA-PEG conjugate.

Once the DOX-PLA-PEG conjugate was synthesized, micelles were formed via
the dialysis method. It was found that the DOX-PLA-PEG conjugate exhibited superior
drug loadings then the control, non conjugated DOX-PLA-PEG conjugate (2.18%
compared to 0.51%). This is attributed to the carbamate linkage which forces the
hydrophobic drug into the core, whereas if it had been free, it would have escaped during
the self- assembly process. When the micelles were incubated in a phosphate buffer, the
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DOX-PLA-PEG conjugate showed a sustained release profile with only 50% of the drug
released over a period of two weeks. In contrast, the non-conjugated micelle exhibited a
burst release in 3 days. The sustained profile of the conjugated DOX-PLA-PEG micelle
can be attributed to the carbamate linkage which takes longer to degrade than the PLA
backbone. Cell studies were also undertaken which showed that not only are the
conjugated micelles taken up more by cells (presumably via endocytotic transport), they
are also more cytotoxic to cancer cells than free doxorubicin.
Recently, target specific micelles have been the focus of many studies. In order to
increase therapeutic efficiency and to reduce the side effects from chemotherapy, Du and
co-workers devised a strategy where they decorated polymeric carriers with a moiety,
such as an antibody for active targeting.17 The antibody used in this study was HAb18 F
(ab′) 2, which was specific for the hepatocellular carcinoma (HCC) tumor, the 3rd leading
cause of death from cancer. The micelles were synthesized utilizing the same method as
the Park group; however, once the micelles were synthesized, the antibodies were then
attached. Although they exhibited lower drug loading efficiencies than naked micelles
(2.19% as opposed to 2.36%), they were taken up more efficiently by cancer cells and
were more cytotoxic towards them compared to naked micelles. This can be attributed to
receptor mediated endocytosis, owing to the antibody moiety on the micelle. From the in
vivo studies, they discovered that the targeted micelles accumulated in the tumor, rather
than accumulating in the organs such as the liver or heart, which is the case in drugs that
are not targeted. This provides an exciting opportunity for drug delivery systems in that it
reduces cardiac toxicity, which is one of the leading side effects of DOX chemotherapies.

Polyesters have also found applications as micro- and nanoparticles, as well. Due
to FDA approval, PLGA has found utilization in many drug delivery systems. A human
growth hormone delivery system under the trademark name Lupron Depot® was the first
FDA approved implantable PLGA microparticle system.4,18 Since then, there have been
reports of microparticles for use in the treatment of asthma19 and they have even showed
promise as a promising drug carrier for local sustained inhalation therapy of pulmonary
diseases.20
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Polyesters have also found usage at the nano-scale level. Owing to their small size,
nanoparticles have been shown to have improved cellular penetration. Throughout the
years, there have been studies in which nanoparticles have been used in many preclinical
trials for treatment of cerebral diseases, osteoporosis, cardiovascular diseases, diabetes, as
well as for regenerative medicine and vaccinations.18 One such example involving the
treatment of endometrial carcinoma utilized the folate receptor (which has been shown to
be over expressed in tumor cells)14 to enhance uptake by cancerous cells. It was found
that not only were the nanoparticles containing the folate receptor more likely to be taken
up by cancer cells, but they were also less toxic to the other organs.21

1.5 Poly(ester amide)s
PEAs are a promising class of biodegradable polymers. They have excellent high
temperature stability, excellent mechanical strength (a result of the H bonding of the
polymer backbone) and crystallinity in some cases. In addition to these qualities, PEAs
also exhibit the high degradability and versatility of the polyesters.22-24 PEAs commonly
consist of three naturally occurring and non-toxic building blocks: α-amino acids, fatty
diacids and diols (Figure 1.6).

Figure 1.6 Poly(ester amide) PEA.
Due to the vast accessibility and choices of these building blocks, many different
types of PEAs have been synthesized which exhibit a wide range of thermal, physical,
mechanical, chemical and biodegradation properties. Also, because they degrade via a
surface erosion type mechanism, they have found usage as drug eluting stents,24-25 as
commercial skin grafts (PhagoBioderm®)26 and have shown promise for future
applications in the area of drug delivery,27-30 transfection agents,31-33 tissue engineering34-
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and as possible candidates for processing of high performance engineering plastics and

photoelectric materials.37
PEAs containing functional groups are advantageous in that their functional
handles allow for the covalent attachment of drug molecules for drug delivery or growth
factors and adhesion molecules, both important components of medical implants and
tissue engineering scaffolds. As a result, there are many examples in the literature that
aim to add functionality to these polymers. They shall be discussed in the following
section, along with their potential applications.

1.5.1 Unsaturated PEAs
One way of adding functionality to a PEA is by incorporating double bonds in the
polymer backbone, or incorporating them as pendant groups. In the first example, Chu
and co-workers used the double bond on the polymer backbone as a reactive site to
conjugate an amine, or a carboxylic acid via a thiol-ene reaction.38 The polymer was
synthesized via a solution polycondensation of the unsaturated monomer, di-pnitrophenol fumarate with either the di-p-toluenesulfonic acid salts of L-phenylalanine
butanediol-1,4-diester, or the di-p-toluenesulfonic acid salts of L-phenylalanine
triethylene glycol diesters. With the polymer synthesized, the thioether was then formed
by reacting the unsaturated PEA or poly(ether ester) amide (PEEA), with either 3mercaptopropionic acid, or cysteamine (Scheme 1.3).
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Scheme 1.3 Synthesis of functional PEA or PEEA with pendant functional groups.
The ether linkage was used as a replacement for the fully aliphatic diol because in
previous work, it was found that the fumarate monomer led to polymers with high
rigidity and crystallinity.39-40 Therefore, the ether linkage was used to increase the
hydrophilicity, flexibility, and biodegradability of the polymers. Thermal properties
indicated that incorporation of the functional groups lowered the glass transition
temperature.
Another way to add functionality using the unsaturated approach has been
postulated by the same group. Instead of using the backbone as the reactive site, the
pendant groups were used to conjugate molecules; this has been accomplished by using
the DL-2-allyglycine monomer which contains a pendant double bond.41 The polymers
were synthesized by a solution polycondensation utilizing the allylglycine monomer, the
di-p-toluenesulfonic acid salts of L-phenylalanine butane-1,4-diester and the di-pnitrophenyl diesters, each with varying aliphatic groups and monomer ratios. The
functionality was then added by conjugating the pendant alkene group with the
corresponding functional thiol to form the carboxylic acid, amine, or sulfonate moiety on
the backbone (Scheme 1.4). The polymers were then cast into films and mass loss studies
were undertaken to determine the effect the length of the chain and the monomer ratio
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had on the degradation. An increase in the methylene chain length was found to
accelerate the degradation of the polymers when the appropriate enzyme was present,
while an increase in the allylglycine monomer lowered the degradation rate. This was
thought to be attributed to the hydrophobicity of the polymer; an increase in the chain
length made it more hydrophobic and thus led to better affinity towards the enzyme. In
contrast, adding more of the allylglycine monomer led to less of the phenylalanine
monomer being incorporated, thereby causing the polymer to be less hydrophobic. As a
result, the degradation rate decreased.

Scheme 1.4 Synthesis of functional PEAs using a pendant double bond approach.

1.5.2 PEAs using the copolymer approach
Another approach to add functionality to the PEA backbone is by copolymerization with
functional monomers, an approach used by many groups with much success.30-31,33,36-37, 41,
42-43

Recent work by Knight et al. have shown that by utilizing an interfacial

polycondensation (as opposed to a solution condensation), the polymers that were
synthesized had higher molecular weights and significantly reduced reaction times.36 In
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brief, the di-p-toluenesulfonic acid salt monomer containing a varying amount of
methylene groups in the diol chain was copolymerized with bis-N-ε-t-Boc-L-lysine
diester and sebacoyl chloride (Scheme 1.5). Previous work indicated that only a small
percentage of the functional groups was required to impart functionality to the PEA.42-43
As a result, the same percentage was used in this work.
The interactions of these poly(ester amide)s with human coronary artery smooth
muscle cells (HCASMCs) were then studied and it was found that all PEAs not only
supported HCASMC attachment, they also led to cell spreading which is indicative of a
proliferative phenotype. Also, in some cases, cell viability was higher than the tissue
culture polystyrene (TCPS), which served as the control. Out of all the PEAs studied, the
one containing the deprotected lysine moiety was the most attractive as it could be used
in future applications to conjugate molecules that regulate cell growth, differentiation and
signaling pathways.

Scheme 1.5 Synthesis of functional PEA via the interfacial polycondensation method.
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PEAs have also found applications in gene delivery. For example, PEAs
containing the bis-L-arginine ester monomer (synthesized from oligo ethylene glycols),
were synthesized and nanoparticles were formed to transfect cells with DNA.33 In this
particular study, the oligo(ethylene glycol) linker was substituted for the diol to not only
increase its solubility, but to also improve transfection compared to previous results.31-32
Solubility was enhanced remarkably, as polymers containing the ether linkage had better
solubilities than their diol counter-parts. Mobility shift assays indicated that an increase
in the methylene chain unit allowed for better DNA complexation. A similar result was
found with the ether linkage to a degree, presumably because the charge density between
two adjacent arginine moieties was too far apart. With respect to transfection efficiency,
the newly synthesized PEAs not only had higher transfection efficiencies, but in some
cases, achieved better transfection efficiencies at a lower cytotoxicity levels than
Lipofectamine2000® (a commercial transfection agent). Subsequent cells studies
indicated that compared to other transfection agents, these newly synthesized PEAs were
less toxic, even at a higher dosage.

1.6 PEAs for drug delivery
Another exciting application for PEAs is in the area of drug delivery. There have been
many ways in which drugs have been encapsulated and delivered over the years and these
different methods shall be the focus of this section.
Throughout the years, dendrimers have garnered a lot of interest for biomedical
applications due to their regular and highly branched three-dimensional globular
structure, low viscosity, high solubility, abundance of functional end groups and internal
cavities. Also, their size and structure can be tuned to ensure biocompatibility and
biodegradability. Dendrimers can also be seen as the analogs of enzymes, proteins,
viruses and antibodies.44 As a result, they are attractive as drug delivery vehicles.
However, a major drawback is their tedious and complex multistep synthesis which
results in expensive products for limited usage in large-scale industrial applications.27 To
this end, hyperbranched polymers can be seen as viable alternatives to dendrimers.
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Hyperbranched polymers consist of highly branched, polydisperse macromolecules with
a treelike topology and a large number of functional groups. In cases where structural
perfection is not a necessity, hyperbranched polymers may be substituted. Unlike
dendrimers, their synthesis is rapid owing to their one-step reactions which results in
economically promising products for small and large-scale industrial applications.
Hyperbranched PEAs have been prepared and have already found applications as drug
delivery vehicles, the most noted example being Hybrane® (Figure 1.7). This polymer
was synthesized via a polycondensation between a cyclic anhydride and a diisopropanol
amine to afford the hyperbranched structure.45 Hybrane® has also found other
applications outside of drug delivery such as in additives in polypropylene fibers to allow
dyeability, suppression of gas hydrates to aid in transportation of gas or oil at low
temperatures and as a paper coating to improve printing speeds.28

Figure 1.7 Structure of commercially available hyperbranched poly(ester amide),
Hybrane®.
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PEA microparticles have been reported for the physical encapsulation of drugs,46
but in general, a problem with microparticles is their large size which causes them to
exhibit rapid uptake by the liver and spleen. To address this, Zilinskas et al. sought to
synthesize the first self-assembled PEA micelle by grafting a hydrophilic block (via the
pendant amine group), in order to form an amphiphilic block copolymer (Scheme 1.6).30
The hydrophilic block grafted was PEG, chosen for its high water solubility, known
biocompatibility in drug delivery applications and its stealthy properties. Micelles were
formed using the nanoprecipitation method and the sizes were suitable for in vivo studies
(<100 nm). Nile red was then used as a model drug and was encapsulated. Nile red was
found to be released over a period of 15 hr at physiological pH, whereas an accelerated
release occurred at pH 5; both rates were reasonable for drug delivery applications. The
enhanced release at the acidic pH was thought to be attributed to the protonation of the
residual pendant amine groups in the micelle core, which increased the hydrophilicity of
the core, thereby favoring drug release. Also, protonation of the drug at acidic pH would
also favor release of the protonated drug molecule into the aqueous environment. Cell
toxicity studies indicated that the micelles were not toxic to HeLa cells in vitro, even at a
high 2 mg/mL concentration.

Scheme 1.6 Formation of amphiphilic block copolymer for self-assembly of PEAs into
micelles.
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1.7 Limitations of Polyesters and PEAs
Although polyesters have been used in many drug delivery applications, they suffer from
an initial burst release in which a considerable amount of drug is released at the start of
the degradation; this burst release may be harmful for in vivo applications. The burst
release is a result of their bulk erosion degradation mechanism,1,9,47 resulting in
accumulation of acidic byproducts in the system.2,9 These acidic byproducts are
detrimental to cell growth and limit the usage of polyesters for tissue engineering.
To circumvent these problems, PEAs have been seen as a viable alternative. As
PEAs often degrade via a surface erosion mechanism,47-50 they are more attractive for
drug delivery systems because they should lead to a sustained drug release over time.
Also, because the degradation byproducts are often natural building blocks, they are
expected to be relatively non-toxic.22,26,51Although their degradation is accelerated in the
presence of enzymes,48-50,52 their degradation in neutral buffer is extremely slow.26,41
Also, one should note that in the biological world, in order for enzymes to be present; the
correct cells must also be present, an idea often overlooked when designing
biodegradable polymers.3 To date, there exists no way to initiate the degradation of
PEAs; they degrade via random uncontrolled hydrolysis of the polymer backbone.

1.8 Stimuli responsive polymers
Over the years there have been an increasing number of examples in the literature that
aim to instigate the degradation of a polymer using a trigger. These polymers contain
specific functional groups that are sensitive to specific stimuli (i.e. light, change in pH or
redox potential). Upon encountering these stimuli, the functional groups react or change
in some manner, releasing the payload (Scheme 1.7). The following section shall discuss
recent advancements in this area, as well as different types of stimuli responsive
polymers.

18

Scheme 1.7 Self-assembly, encapsulation of drug and subsequent release.

1.8.1 Acid sensitive polymers
Change in pH is a particularly useful type of stimulus for drug delivery agents, as there
are numerous pH gradients in both normal and diseased states. It has been well
documented that the extracellular pH of tumors is lower than that of normal tissue, with
an average pH of 7.0, as opposed to the normal physiological pH of 7.4.53 The pH drops
to about 5.5-6.0 in the endosomes and is close to 5.0 in the lysosome.53 As a result, drug
carriers may exploit this gradient to deliver their payload to a specific area without
harming nearby tissues. There have been numerous examples that have utilized this pH
gradient and they shall be the focus of this section.
One of the ways in which a polymer may be sensitive to acidic pH is by
incorporating an acid degradable linkage in the hydrophobic part of the backbone.53-56
Upon forming a self-assembly and encountering an acidic environment, the acid sensitive
linkage is cleaved which leads to disruption of the micelle core and release of any
payload, if present. Chen and coworkers have synthesized polycarbonates (Scheme 1.8),56
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containing different electron donating groups that were able to form micelles. At
physiological pH there was negligible degradation. However, the half-lives at pH 4 and 5
were 1 and 6.5 hrs, respectively. It was found that the polymer containing the two
methoxy groups degraded faster, presumably because of their electron donating
properties. The drugs paclitaxel and doxorubicin were then loaded with efficiencies of 65
and 60% respectively; release studies were then undertaken. In vitro studies showed that
release was accelerated at pH 4 and 5, as opposed to 7.4. For example, within 48 hr the
release of both drugs were 98, 89, and 44% at pHs 4, 5, and 7.4, respectively.

Scheme 1.8 Synthesis of polycarbonate and subsequent degradation.
In some cases, a drug may be conjugated to a copolymer by an acid-labile
linker57-59, so that the polymer backbone remains intact. This is beneficial in that no
further modification of the drug is required and can be generalized to different drugs
without changing the linkage. In a particular example,59 doxorubicin was conjugated to a
double hydrophilic block copolymer of poly(ethylene glycol)-hyperbranchedpolyglycerol (PEG-hb-PG) by a hydrazone linker (Figure 1.8). Micelles were formed and
it was found that the release was accelerated at pH 5, as opposed to pH 7.4 (71%
compared to 53.6% after 48 hr). Laser fluorescence microscopy proved that the micelles
were internalized within the cell and cell viability studies indicated that the micelles were
not cytotoxic to HeLa cells, due to the drug.
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Figure 1.8 Doxorubicin conjugated to PEO-hb-PG by a hydrazone linkage.

1.8.2 Reduction sensitive polymers
There exists a large difference in reducing potential between the intracellular and
extracellular environments of the cell.60 It has also been proven that tumor tissues are
highly reducing.61-62 As a result, there have been many drug delivery vehicles that aim to
use this reduction potential as a trigger to initiate degradation. The linkage that is
sensitive to this trigger is the disulfide bond, which can either be incorporated into the
main chain, or may be used as a cross-linker.
A disulfide bond may be incorporated into the polymer backbone so that upon
reduction, the polymer chain is cleaved, thereby commencing degradation. A class of
polymers that incorporates the disulfide into the polymer backbone is the poly(amido
amine)s, which have gained usage as transfection agents due to their buffering
capacities.63-65 In a particular example,63 Zhong and co-workers synthesized a series of
reducible poly(amido amine)s in order to compare their buffering capacities (Scheme
1.9). Buffering capacity is thought to play a role in endosomal escape of polyplexes
(“proton sponge theory”).66 These polymers were synthesized by a Michael addition
between various amines to the disulfide-containing cysteamine bisacrylamide. It was
found that the derivatives containing the dimethylamino as the pendant group were the
least effective, mainly because protonation of the tertiary nitrogen on the backbone was
suppressed.
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Scheme 1.9 Derivatives of reducible poly (amido amine)s and their degradation.
Using the ABOL derivative as an example, the degradation was monitored in nonreducing conditions and there was only a 5% decrease in Mw after 3 days and up to 60%
decrease after 20. In contrast, when dithiothreitol (DTT, a well known reducing agent)
was added, the polymer completely degraded within 5 minutes. The polymer was found
to retain DNA effectively and was also able to release it once DTT was added. Cell
toxicity studies indicate that the reducible poly(amido amine)s have better cell viabilities
(~100%) than the control, polyethyleneimine (~20%). These polymers were also found to
have better transfection efficiencies than the control.
Another way to add reducing functionality to a polymer is by adding the reducing
linkage in the linker.67-69 Using a recent example,67 a new gene carrier composed of
poly(L-lysine) and PEG was synthesized containing two labile linkages - one responsive
to a decrease in pH and the other responsive to a change in reduction potential (Figure
1.9). It was reasoned that by adding a reduction labile PEG shell (which would aid in
intracellular uptake), the acid linker would disintegrate in the endosome and aid in release
of genetic payload to the cytosol. Although the buffering capacity of this catiomer
(mPEG-SS-PLL15-Star) was reduced compared to the control polyethyleneimine, the cell
viability profiles were enhanced for this novel polymer. The catiomer was also able to not
only condense DNA, it was also able to release it upon applying either one of the stimuli
(reduction in pH, change in reduction potential).
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Figure 1.9 Dual stimuli responsive catiomer, mPEG-SS-PLL15-Star.

1.8.3 Photochemically sensitive polymers
Light as a stimulus is attractive because it is non-invasive and can be applied from an
external source for a short period of time with high spatial and temporal precision.70
Recently, near infrared (NIR) light has achieved much attention due to its ability to
penetrate deeper into the tissue and because it is less harmful to cells.70-74 Functional
groups that are sensitive to light have been implemented into polymers to stimulate their
degradation. These functional groups are o-nitrobenzyl70,72, 75-79 and derivatives of
bromocoumarin.70-71,73-74,77
One example incorporating the o-nitrobenzyl moiety is illustrated by Dong and
coworkers.79 In this particular example, a new polypeptide was synthesized by the ring
opening polymerization (ROP) of a photoresponsive S-(o-nitrobenzyl)-L-cysteine-Ncarboxyanhydride to form the corresponding poly(S-(o-nitrobenzyl)-L-cysteine)-bpoly(ethylene glycol) (pNBC-b-PEG) (Scheme 1.10). The copolymers were found to
form spherical micelles and irradiation for 20-40 minutes at 365 nm was required to
completely remove the photolabile groups, depending on the polarity of the solution.
Upon encapsulation of DOX and irradiating for different time periods (i.e. 2, 5 and 10
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min), it was found that DOX release became faster with increasing irradiation time; this
demonstrates that DOX can be released in a controlled manner by varying irradiation
time.

Scheme 1.10 Synthesis and photo-cleavage of pNBC-b-PEO.
NIR irradiation presents another way to photochemically degrade a polymer. In
order to make their polymers sensitive to NIR light, Zhao et al. added coumarin moieties
to the glutamic acid monomers in order to increase its hydrophobicity and thus assist
micelle formation in an aqueous solution.73 It was reasoned that upon self-assembly of
the block copolymer and subsequent irradiation with NIR light, the hydrophilichydrophobic balance of the micelle would be disrupted, leading to destabilization of
micelles in solution (Scheme 1.11). When these micelles were irradiated at 794 nm in
solution, it was found that the absorbance corresponding to the coumarin groups
disappeared after 220 minutes of irradiation. Two different drugs were encapsulated and
then released with varying times. In the case of the rifampicin antibiotic drug, there was
~75% release after 55 hours, compared to ~10% in a sample that was not irradiated. For
paclitaxel, the release was found to be 50% after 145 hours, with neglible release from
the control. The decreased release is thought to be attributed to the hydrophobic nature of
paclitaxel, compared to rifampicin which is amphiphilic.
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Scheme 1.11 Synthesis and photo-cleavage of PEG-b-p(LGA-co-COU).

1.9 Self-immolative spacers
Self-immolative spacers have been involved in prodrug synthetic strategies since the
early 1980s. It was during this time that Katzenellenbogen and coworkers hypothesized
that adding a linker in between the drug and the specifier would not only prevent
premature release of the drug, it would also increase accessibility of the cleavage site,
thereby enhancing release (Figure 1.10a) .80 As a result, the first ever self-immolative
spacer was created which was based on 4-aminobenzyl alcohol. Unmasking of the
aromatic amine began a 1,6-elimination which led to an electronic cascade, resulting in
the release of CO2, followed by the free drug or other leaving group (Figure 1.10b). Other
examples of self-immolative spacers are the ones capable of cyclization. In the first
example, the functional group undergoes 1,5-cyclization to form the corresponding
lactone (Figure 1.10c),81 whereas in the second example, due to three interlocking methyl
groups; cyclization forms the corresponding coumarin (Figure 1.10d).82 The applications
of these spacers are diverse and they range from applications in prodrug strategies,83-85
signal amplifiers,86-87 and as latent fluorophores.88-89 Their applications in linear polymers
shall be discussed herein.
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Figure 1.10 a) Schematic of a prodrug consisting of: specifier (trigger), spacer and drug;
b) general structure of electronic cascade spacers; c) general structure of cyclization
spacers; d) Rapid reaction of a trimethyl lock acid to form a δ-lactone.

1.9.1 Self-immolative linear polymers
When self-immolative spacers were first introduced, they were incorporated into
dendritic systems for drug delivery applications with much success. They were
advantageous in that only one single event was required to release multiple drug
molecules; a signal amplification of sorts.90-94 However, the number of groups that can be
incorporated on a dendritic periphery is limited by steric hindrance and the higher
generations require additional synthetic steps.95 As a result, the first linear selfimmolative polymer was created by the Shabat group.96 The polymer was created by
polymerizing a phenyl carbamate derivative and then capping it with an enzyme-labile
trigger, 4-hydroxy-2-butanone. The protein BSA then catalyzed the removal of the trigger
and the florescent molecule was emitted over a period of ten hours (Scheme 1.12). Since
it has been proven that the cyclization mechanism is slower than the elimination
mechanism, cyclic spacers have been incorporated by the Gillies group into linear
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polymers to adjust the rate of degradation. For example, polymer 1.69 (Scheme 1.13)
degrades by alternating cyclization and elimination reactions at a slower rate than
polymer 1.66.97

Scheme 1.12 Disassembly of linear self-immolative polymer.

Scheme 1.13 Disassembly of self-immolative polymer by alternating and 1,6-elimination
reactions.
Previous studies that require light as a trigger have involved long irradiation
times, and as a result, do not seem to have practical applications in the biological realm.
In order to evade this issue, Almutairi and coworkers designed a system that was
sensitive to brief irradiation.71 Using polymer 1.69 from the Gillies group as a starting
point, they capped the polymer with a trigger that was sensitive to either UV (onitrobenzyl), or NIR (4-bromo-7-hydroxycoumarin) light to compare the effect each had
on degradation rate. Degradation was monitored by SEC and it was found that the
polymer triggered under UV light for 10 min was fully degraded after 24 days. In
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contrast, the polymer triggered under near IR light for 10 min was 70% degraded after 4
days. Nanoparticles were created from these polymers and florescence dropped to 65%
and 40% after 1 and 5 minutes of irradiation. The polymers were also subjected to
toxicity studies and it was revealed that the polymers and degradation products were
tolerated as well as the FDA approved polymer, PLGA.
As there have been studies that indicate that quionone methides can contribute to
toxicity,98-99 Gillies and coworkers synthesized a self-immolative polymer consisting
entirely of cyclization spacers.100 The spacers that were chosen for this particular study
consisted of 2-mercaptoethanol and N,N’-dimethylethylenediamine. These spacers
cyclized to their corresponding cyclic thiocarbonate and cyclic urea respectively (Scheme
1.14). Degradation experiments were carried out and the polymer was found to be 80%
degraded after 10-14 days, with the control polymer (with no reducing agent added),
hardly exhibiting degradation over the same time period. Related cyclization spacers
based on 4-aminobutyric acid were also developed by Gillies and coworkers with the aim
of obtaining more rapid cyclization kinetics. However these have not yet been
incorporated into linear polymers (Figure 1.11.) .101

Scheme 1.14 Disassembly of a reduction sensitive self-immolative polymer.

Figure 1.11 4-aminobutyric acid.
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Although there have been many applications in which the so called “trimethyl
lock” spacer has been used in prodrug applications,102-103 their use in the development of
cleavable polymers has also been recently reported.104 Redox-sensitive nanoparticles
were synthesized that had the trimethyl-locked benzoquinone moiety monomer. This
monomer was polymerized with adipoyl chloride and nanoparticles were subsequently
formed using the emulsion method (Scheme 1.15). It was reasoned that upon reduction of
the benzoquinone moiety, the functional amine groups would be revealed, causing
chemical changes in the nanoparticles which would lead to swelling or dissolution at
physiological pH. Paclitaxel was loaded into these polymers at an efficiency of 77.9%
and redox-triggered drug release was carried out in vitro.

Scheme 1.15 Synthesis and subsequent reduction of redox-sensitive polymer based on
trimethyl-locked benzoquinone.

1.10 Objective of this thesis
The aim of this thesis was to combine the structures of PEAs bearing pendant functional
groups with the concepts of self-immolative spacers to develop PEAs for which the
degradation of the backbone can be triggered by an external stimulus. As described
above, the Gillies group has previously demonstrated that amino acids, such as lysine and
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aspartic acid bearing protected pendant functional groups can be incorporated into PEAs.
For this thesis it was proposed that by the use of amino acids such as L-2,4diaminobutyric acid and DL-homocysteine into the PEA backbone, it would be possible
to trigger the cleavage of the PEA backbone upon cleavage of a protecting group or
“trigger” on the amine or thiol moiety respectively (Scheme 1.16). Described in the
following sections are studies to demonstrate that the 4-amine on an aliphatic ester
derivative of L-2,4-diaminobutyric acid (DAB) does undergo cyclization to the
corresponding lactam when the free 4-amine is revealed and that similarly, the thiol on
DL-homocysteine (Hcy) cyclizes to form the thiolactone when the thiol is revealed. The
synthesis of the target polymers is also described, followed by studies of their
degradation in solution and in thin films. In addition, the development of a
photoresponsive version of the polymer containing DAB is also described, followed by
studies of its degradation.

Scheme 1.16 Degradation of PEA via a triggered cyclization reaction
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Chapter 2
Controlled degradation of PEAs via cyclization of pendant
functional groups
2.1 Introduction
Polymers that degrade under biological conditions have become a part of our daily lives
due to their utilization as sutures,1,2 stents,3,4 drug delivery vehicles, 5,6-9 packaging for
medical and non-medical applications 2,5,10 and as scaffolds for tissue engineering.1,11 Of
the different types of the polymers used for these applications, the poly(hydroxyacid)s
have garnered the most attention; receiving FDA approval in some cases.1,2,9,10 Although
widely used in many applications, their bulk degradation results in many acidic
byproducts,1,11-13 resulting in inflammation which is undesirable in many medical
applications. Also, their lack of functionality and inability to exhibit stimuli-mediated
degradation are other limitations of this class of polymers.
PEAs have been proposed as an alternative class of materials to polyesters. They
are composed of amide and ester bonds which offer the thermal and mechanical
properties derived from polyamides, while giving the degradability and flexibility of
polyesters.14-16 In addition, their monomers can be selected from simple metabolic
intermediates such as amino acids and dicarboxylic acids, such that their degradation by
surface erosion results in non-toxic, non-inflammatory byproducts.14,17-18Another
advantage is that by using amino acid monomers with functional handles, PEAs with
functional groups can be prepared. These functional handles may be used for the
conjugation of drug molecules in delivery systems, cell signaling molecules in tissue
engineering scaffolds and as a means to tune the properties of the polymer.19-23 As a
result, there have been many instances of PEAs being used for biomedical applications
such as drug delivery,24-27 gene carriers28-30 and as scaffolds for tissue engineering.19-20,31
However, much like polyesters, their degradation is relatively uncontrolled and although
they have been known to degrade under enzymatic conditions in vitro, their degradation
under neutral conditions is still slow.
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The ability to trigger degradation under conditions such as photochemical, or
changes in pH or redox potential is advantageous in that a polymer backbone may be
stable to for extended periods, but degrades once the appropriate stimuli is applied;
resulting in a controlled degradation. As a result, there have been many polymers that
have been synthesized that are sensitive to stimuli such as light,32-41 changes in pH,42-49 or
redox potential.50-56 Another way to impart controlled degradation to a polymer has been
through the incorporation of self-immolative spacers. The first self-immolative spacers
were based on 1,6-elimination reactions.57 They first found use in prodrug strategies
where unmasking of an aromatic alcohol, amine, or thiol allowed it to become electrondonating, initiating an electronic cascade leading to release of a free drug or other leaving
group. This strategy has since been applied to drug delivery applications.58-62 Although
initial work in the field of dendrimers was successful, the additional synthetic steps for
the higher generations prevented its use for future applications, thereby inspiring the use
of linear self-immolative polymers.63 It was later demonstrated by our group that by
incorporating self-immolative spacers capable of cyclization, the rate of degradation
could be adjusted.64 As there have been studies that indicate that the quinone methide
intermediated formed during the elimination reaction can result in toxicity, 65-66 the
Gillies group also synthesized a self-immolative polymer consisting entirely of
cyclization spacers.67 Although the degradation required several days due to the slow rate
of the diamine cyclization, related cyclization spacers based on 4-aminobutyric acid have
since been developed by Gillies and coworkers with the aim of obtaining more rapid
cyclization kinetics.68 However, these have not yet been incorporated into linear
polymers.
The aim of this work is to combine the structures of PEAs bearing pendant
functional groups, with the concepts of self-immolative spacers, to develop PEAs for
which the degradation can be triggered by an external stimulus. Since previous work
from our group has demonstrated that amino acids such lysine,20,23,27 and aspartic acid69
can be incorporated into the PEA backbone and subsequently deprotected following
polymerization, for this work we propose incorporating amino acids such as L-2,4diaminobutyric acid and DL-homocysteine into the PEA backbone. These amino acids
would allow triggering of the degradation of the PEA backbone following deprotection of
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a thiol, or amine moiety, respectively. Described in the following sections are studies to
demonstrate that the 4-amine on an aliphatic ester derivative of L-2,4-diaminobutyric acid
(DAB) does undergo cyclization to the corresponding lactam when the free 4-amine is
revealed and that similarly, the thiol on DL-homocysteine (Hcy) cyclizes to form the
thiolactone when the thiol is revealed. The synthesis of the target polymers is also
described, followed by studies of their degradation in solution and in thin films. In
addition, the development of a photoresponsive version of the polymer containing DAB
is also described, followed by studies of its degradation.

2.2

Results and discussion

2.2.1 Molecular design
The choice of pendant functionalities that would induce cyclization, and thus
backbone cleavage of the PEAs was based on previous work in the Gillies group. DeWit
and Gillies recently demonstrated that the amine moiety of 4-aminobutyric acid
derivatives cyclized rapidly upon phenyl esters to provide the corresponding 5-membered
lactam.68 Recent work by Chen et al. showed that a thiol moiety could be more
nucleophilic than the amine at the neutral pH of 7.4, and thus undergo cyclization to the
corresponding 5-membered ring more rapidly.70 Based on these data, DAB and Hcy were
the target amino acids for incorporation into the PEA backbone.
Following previous synthetic protocols for PEAs, it should be possible to prepare
diamine-diester derivatives of these amino acids with aliphatic diols and polymerize these
with aliphatic dicarboxylic acid derivatives by solution or interfacial routes. The
interfacial route was selected as we have found that it leads to higher molecular weight
(MW) polymers with shorter reaction times.20,26 This dictates the use of sebacoyl chloride
as the dicarboxylic acid derivative as the shorter chain derivatives are too soluble in the
aqueous phase of the CH2Cl2-water mixture that is used for the interfacial
polymerization, resulting in premature monomer hydrolysis. 1,4-Butanediol was chosen
as the aliphatic diol because it is easy to work with synthetically. In principle, it would be
feasible to polymerize sebacoyl chloride with the diamine-diester derivative of DAB or
Hcy (having protected side chain moieties). However, as with other PEAs containing
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pendant functional groups, these DAB and Hcy monomers are relatively expensive to
prepare, and to impart degradability to the target PEAs, it is not necessary to have a selfimmolative spacer at every repeat unit. Thus the functional DAB and Hcy monomers
were diluted with an L-phenylalanine (Phe)-1,4-butanediol diester-diamine to provide
20% of the DAB or Hcy monomer is the resulting polymer. This Phe monomer was
selected due to its ease of synthesis and for the thermal and mechanical properties of the
resulting polymer which enhance the polymer’s processability in melt.71 Thus, the
specific target polymers 2.1 and 2.2 containing DAB and Hcy are shown in Figure 2.1.
A t-butyloxycarbonyl (Boc) protecting group was selected for the DAB monomer.
Although this Boc group cannot be cleaved under physiological conditions, it can be
readily cleaved with trifluoroacetic acid (TFA), allowing the degradation process to be
readily studied. It can later be replaced with a more specific trigger as described in
section 2.2.7 of this thesis. A dithiopyridyl moiety was selected for the Hcy monomer as
it can be cleaved by biological reducing agents such as glutathione, which are present at
elevated levels in the intracellular environment as well as in hypoxic tissues such as
tumors.72-74 In addition to the target polymers, two small molecule derivatives 2.3 and 2.4
of DAB and Hcy were targeted in order to study the cyclization rate upon removal of the
side chain protecting group and to verify that the cyclization was faster than background
hydrolysis of the ester.
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Figure 2.1 Chemical structures of proposed PEAs incorporating a) DAB monomer, b)
Hcy monomer, c) DAB ester with Boc protecting group, d) Hcy ester with dithiopyridyl
protecting group.

2.2.2 Synthesis of small molecule model compounds 2.3 and 2.4
The preparation of the model compounds 2.3 and 2.4 was necessary because the rates of
the specific cyclization reactions to be utilized in this work had not been explicitly
studied and it was important to understand their rates in the context of the future polymer
degradation experiments. While phenyl ester derivatives of 4-aminobutyric acid have
been previously reported by our group, an ethyl ester was selected for this work as it
more closely mimics the aliphatic ester in the target polymer. The synthesis of this DAB
ester was investigated using two different routes. In the first approach (the direct-method
approach, Scheme 2.1), a Fischer esterification was attempted. The reaction conditions
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involving sulfuric acid proved unsuccessful, presumably due to the residual water in the
acid. Another attempt was made using dry hydrochloric acid formed from calcium
chloride; 75 however, this method proved to be more labor-intensive as acid had to be
constantly replenished and finally, neutralized with base once the reaction was complete.

Scheme 2.1 Unsuccessful synthesis of DAB ethyl ester using direct-method approach.
As the direct-method approach was unsuccessful, the synthesis was performed
using the commercially available starting material, (9-fluorenylmethoxycarbonyl) FmocDAB(Boc)-OH that was in hand for preparation of the polymerization monomer as a
starting point (Scheme 2.2). First, the ethyl ester was synthesized using a N,N’dicyclohexylcarbodiimide (DCC)-mediated coupling with catalytic amounts of 4(dimethylamino) pyridine (DMAP) and 4-(dimethylamino)-pyridinium-4toluenesulfonate (DPTS) to afford 2.9. With the ester in hand, the protecting group was
removed in order to make the ester soluble in the phosphate buffer. The Fmoc group was
removed using a catalytic amount of 1,8-diazobicyclo[5.4.0]undec-7-ene (DBU) and
excess 1-octanethiol, providing 2.3.
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Scheme 2.2 Formation of DAB ethyl ester.
As shown in Scheme 2.3, the reduction sensitive Hcy ethyl amino acid was first
synthesized by protecting the hydrochloric acid salt of thiolactone Hcy derivative 2.10
with Boc to form 2.11 and later ring opening of the thiolactone with lithium hydroxide to
give 2.12. The disulfide bond was installed by reacting 2.12 with 2,2’- dipyridyl disulfide
and a catalytic amount of acetic acid to give 2.14. The ethyl ester was then formed by
coupling ethanol to 2.14 using DCC with catalytic amounts of DMAP and DPTS.
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Scheme 2.3 Formation of Hcy ethyl ester.

2.2.3 Kinetic studies on small molecule model compounds
The cyclization of the ethyl ester derivatives of DAB and Hcy were first investigated in
pH 7.4 phosphate buffered D2O. In the case of the DAB derivative 2.3, the Boc
protecting group was removed immediately prior to the study, providing the salt 2.16
(Scheme 2.4 a).However, the Boc protected compound 2.13 was also studied as a control
compound in order to determine the rate of background ester hydrolysis. In the case of
the Hcy derivative 2.4, DTT was added to cleave the disulfide bond in the Hcy ester,
providing 2.17 (Scheme 2.4 b). A control without DTT addition was also performed for
compound 2.4. The rates were determined by quantifying the amount of ethanol in
comparison to ethyl ester by integration of their respective peaks in the 1H NMR
spectrum.
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Scheme 2.4 a) Deprotection of Boc group, b) reduction of dithiopyridyl moiety.
As shown in Figures 2.2 and 2.3 by comparing the rates of ethanol evolution for
compounds 2.16 and 2.17 with their respective control compounds 2.3 and 2.4 having
protecting groups on the side chains, the rate of cyclization is faster than that of
background ester hydrolysis. Fitting of the data to a first order rate law (appendix) gave
half-lives of 6 hr and 2 hr for the DAB and Hcy monomers, respectively. In contrast, the
half-lives for the controls 2.3 and 2.4 were 42 and 53 hr, respectively. As shown in Figure
2.4 for the DAB derivative 2.16, the NMR spectroscopic analysis of the products was
consistent with a majority of the expected cyclization product along with a small amount
of background hydrolysis product. As shown in Figure 2.5 for the Hcy derivative, the
expected cyclization product was also predominant in the case of this molecule.
Assignment of these spectra was facilitated by comparison with the spectra of pure DAB
and Hcy in the same buffer (appendix).
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Figure 2.2 Kinetics of degradation for compound 2.16 and background hydrolysis of 2.3
in a 0.1 M, pH 7.4 phosphate buffer.
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Figure 2.3 Kinetics of degradation for compound 2.17 and background hydrolysis of 2.4
and background hydrolysis in a 0.1 M, pH 7.4 phosphate buffer.
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Figure 2.4 1H NMR spectra in 0.1 M, pH 7.4 phosphate buffered D2O of a) DAB
derivative 2.16 immediately following dissolution in the buffer. b) After 5 hr in the same
buffer. c) After 10 hr in the same buffer.
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Figure 2.5 1H NMR spectra in 0.1 M, pH 7.4 phosphate buffered D2O of a) Hcy
derivative 2.17 immediately following dissolution in the buffer. b) After 5 hr in the same
buffer. c) After 10 hr in the same buffer.
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For comparison purposes, spectra of the time dependent background hydrolysis of the
control molecules 2.3 and 2.4 are shown in the appendix. The DAB ethyl ester 2.3
undergoes clean hydrolysis to form DAB and ethanol as expected. On the other hand, in
the absence of DTT addition, the Hcy derivative 2.4 appears to undergo another reaction
in addition to simple hydrolysis. As the disulfide bond, and in particular the activated
dithiopyridyl group, is susceptible to attack by a variety of nucleophiles, it is
hypothesi ed that the α-amine attacks this bond to generate a five membered sulfenamide
(Scheme 2.5).

Scheme 2.5 Formation of five membered sulfenamide.
This functional group has recently found usage in polymers that are quite stable
to basic and neutral conditions, but degrade once the pH decreases.76-77 This side reaction
was not observed for model compound 2.17 due to the rapid cleavage of the dithiopyridyl
group and would not be expected in the target polymer as the α-amines would be tied up
as amides in the polymer backbone. Thus, despite this unexpected side reaction of the
control compound, these kinetic studies showed that the cleavage of the side chain
protecting groups could induce rapid cyclization reactions in DAB and Hcy derivatives,
showing the promise of these monomers for application in the triggered degradation of
PEAs.
As it has been established by our group and others that the choice of solvent
affects the rates of cyclization of self-immolative spacers,33,78-79 the cyclization kinetics
for the small molecule model compounds were also evaluated in 7:2:1 ratio of DMSO:
acetone –D6: 0.1 M, pH 7.4 phosphate buffered D2O. This solvent mixture was selected
as it was found to be one of only a few aqueous solvent mixtures that could dissolve the
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target polymers 2.1 and 2.2. Initially, studies were performed at 37°C and NMR
spectroscopy was used to evaluate the degree of ethanol evolution over time for
compounds 2.3, 2.4, 2.16, and 2.17. However, preliminary experiments indicated that the
rate of ethanol evolution was extremely slow for all compounds. This is consistent with
our observations that the cyclization rate is much slower in aqueous solvent mixtures
with increasing organic content. In order to accelerate the kinetics to occur over a more
readily measurable time scale, the temperature was increased to 70 °C. The rates of
ethanol evolution for the DAB derivative 2.16 and the protected control compound 2.3
are shown in Figures 2.6 and their respective half-lives were found to be 3 and 14 days
respectively.
The kinetics for the Hcy derivative 2.17 are shown in Figure 2.7 and the
corresponding half-life was found to be 52 days. Unfortunately it was not possible to
evaluate the control compound 2.4 in this experiment as the dithiopyridyl group was
rapidly cleaved from this molecule, likely by the same sulfenamide mechanism described
above. In addition, examination of the 1H NMR spectra of 2.17 throughout the
experiment revealed that it was converted to an unexpected intermediate byproduct that
subsequently reacted to release ethanol. Although the nature of this intermediate was not
identified conclusively, it is possible that as described above for control compound 2.4,
conversion to a cyclic sulfenamide occurred, in this case via disulfides of 2.4 with itself
or with DTT, that might exist transiently throughout the reaction. This sulfenamide could
then hydrolyze to reveal the thiol, capable of cyclizing or alternatively undergo simple
hydrolysis to release ethanol. It was difficult to distinguish between these pathways due
to the complexity of the NMR spectra (appendix) but either mechanism would explain
the slow kinetics. It appears that this side reaction does not occur when the thiol
cyclization is rapid as for 2.17 in pure aqueous buffer, but when the reaction is slowed by
the organic solvent there is an opportunity for it to occur. This would explain the reversal
of relative rates with the Hcy monomer faster in pure buffer and the DAB monomer
faster in 7:2:1 DMSO:acetone:buffer. Again, this side reaction would not be expected to
occur during the degradation of the polymer.
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Figure 2.6 Kinetics of degradation for compound 2.16 and background hydrolysis of 2.3
in a DMSO: acetone –D6: 0.1 M, pH 7.4 phosphate buffer (D2O).
50

Ethanol released (%)

45
40
35
30
25
20
15
10
5
0
0

10

20

30

40

50

Time (days)

Figure 2.7 Kinetics of degradation for compound 2.17 in a DMSO: acetone –D6: 0.1 M,
pH 7.4 phosphate buffer (D2O).
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2.2.4 Synthesis of polymerization monomers
In order to prepare the target polymer 2.1, it was necessary to prepare a diamine-diester
derivative of DAB with 1,4-butanediol having free -amines and protected -amines. As
shown in Scheme 2.6, the synthesis began with the commercially available orthogonally
protected amino acid, 2.7. The diester was synthesized by coupling 2.7 to 1,4-butanediol
using a DCC, DMAP and DPTS to afford 2.25. The Fmoc group was then removed using
a catalytic amount of DBU and an excess of 1-octanethiol.

Scheme 2.6 Synthesis of DAB monomer.
The synthesis of the diamine-diester derivative of Hcy was performed by first
coupling the protected Hcy 2.14 with 1,4-butanediol using DCC, DMAP and DPTS to
provide 2.27. The target monomer was then obtained by removing the Boc groups with
TFA to give 2.28 (Scheme 2.7).
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Scheme 2.7 Synthesis of Hcy monomer.

2.2.5 Synthesis of polymers
As described above, the target polymers were prepared by an interfacial polymerization
in CH2Cl2/water. For the preparation of target polymer 2.1 and 2.2, sebacoyl chloride (1.0
equiv.) was dissolved in CH2Cl2 and the solution was added drop wise to a solution of the
diesters 2.26 or 2.28 (0.2 equiv.) and 2.2980 (0.8 equiv.) in aqueous Na2CO3 (Scheme 2.8
and Scheme 2.9). The reaction mixtures were then stirred for 24 hr, after which the
polymers were then purified by dialysis in N,N-Dimethylformamide (DMF). A control
polymer 2.3120 without any DAB or Hcy monomer was also prepared (Scheme 2.10).
SEC (table 2.1) in DMF indicated that the polymers had Mn’s ranging from 91 800 –
155,500 g/mol relative to polystyrene standards and polydispersity indices (PDIs) from
1.22-1.24. The low PDIs and relatively high Mn’s can be attributed to the dialysis step
which removes lower MW polymers in addition to low MW byproducts. The Boc
protecting groups could be removed from polymer 2.1 by treatment with TFA, providing
polymer 2.30. A reduction in Mn was observed as a result of the deprotection process
which has been reported by our group,20,81 as well as others.16,19 This is in part a result of
the interaction of the amino groups of the polymer with the column during SEC.
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Scheme 2.8 Synthesis of and deprotection of PEA incorporating 20% DAB.

Scheme 2.9 Synthesis of PEA incorporating 20% of Hcy.
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Scheme 2.10 Synthesis of control polymer.
Yield

Mn

Mw/ Mn

Polymer

(%)

(g/mol)

(PDI)

2.1

65

155, 500

1.23

2.2

60

98, 300

1.24

2.30

87

91, 839

1.22

2.31

78

63, 600

2.65

Table 2.1 Yields and molecular weight data for functional PEAs and non-functional
PEAs.
Incorporation of the DAB and Hcy monomers into the PBSe backbone was verified by
1

H NMR spectroscopy. As shown in Figure 2.8a, in comparison to the control polymer

2.31, in polymer 2.1 a new peak arises at 1.36 ppm which corresponds to the methyls of
the Boc group. Another peak appears at 4.21 ppm which belongs to the α-proton of the
DAB monomer. In addition, there is a peak at 6.78 ppm corresponding to the carbamate
N-H of the Boc group that, upon addition of TFA to form 2.30, disappears (Figure 2.8 b)
along with the peak attributed to the methyls of the Boc group. In the case of polymer
2.2, the new peaks arise in the aromatic region that corresponds to the pyridyl moiety of
the Hcy monomer as well as another at 4.39 ppm that corresponds to the α-proton of this
monomer (Figure 2.9).
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Figure 2.8 1H NMR (DMSO-D6, 600 MHz) spectra of a) PBSe incorporated with 20%
DAB monomer, protected version b) PBSe incorporated with 20% DAB monomer,
deprotected version.
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Figure 2.9 1H NMR (DMSO-D6, 600 MHz) spectra of PBSe incorporated with 20% Hcy
monomer.

2.2.6 Solution degradation of polymers
Due to the hydrophobic nature of the polymers 2.1, 2.2, and 2.30, they were soluble
primarily in organic solvents such as chloroform, CH2Cl2, DMSO and DMF. In order to
degrade the polymers, varying ratios of different organic solvents with 0.1 M, pH 7.4
phosphate buffers were experimented with. For the study of the polymer degradation in
solution, it was found that the mixture that gave the best solubility was a 7:2:1 ratio of
DMSO: acetone–D6: 0.1 M, pH 7.4 phosphate buffered D2O. Deuterated solvents were
chosen with the goal of monitoring the degradation process by NMR spectroscopy.
Having already determined from the monomer cyclization kinetics that the cyclization
reactions would be significantly slowed due to the high organic solvent content, the
degradation study was performed at 70°C for a period of twelve days. In the case of
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polymer 2.2, DTT was added to cleave the pendant disulfides and initiate degradation of
this polymer. Polymer 2.30 was used as is, because the Boc protecting group had already
been removed, making the pendant amine capable of cyclization. The Boc protected
polymer 2.1 was used as a control for these studies, whereas the control polymer 2.31
was insoluble under these conditions and could not be included in the solution
degradation study.
The degradation of the 3 polymers was monitored by 1H NMR spectroscopy. The
emergence of new peaks was observed (appendix). However, the complexity of the
spectra and overlapping peaks made it impossible to quantify the degree of degradation.
Therefore, the degradation was monitored by SEC. This was done by removing aliquots
of the solution periodically, removing the solvent and then dissolving the material in
DMF for SEC analysis. As shown in Figure 2.10, the deprotected polymers showed a
much more rapid decrease in MW than the protected polymer. For example, whereas
polymer 2.1 exhibited a 50% reduction in Mn over two weeks, polymer 2.30 showed a
90% decrease in Mn over the same period. The same trends were observed when
examining changes in Mw (Figure 2.11). In the case of polymer 2.2, molecular weight
decreased by as much as 94% in 12 days, which demonstrates the faster rate of
cyclization of the thiol group over the amine; this enhanced rate was also seen in the
model ethyl ester studies in pure phosphate buffer, suggesting that the side reaction, and
resulting increased cyclization half-life observed in the organic solvent mixture was
indeed likely the result of the free -amine that was present in the model compound but
not in the polymer. Figure 2.12 and 2.13 show the evolution of the SEC traces over time
for polymer 2.1 and 2.30 respectively. Overall, these results show that the rates of
polymer degradation are much faster for the polymers upon cleavage of the moiety
protecting the pendant groups, confirming that the strategy should be a viable approach to
creating stimuli responsive PEAs.
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Figure 2.10 Molecular weight data for protected and deprotected PEAs.
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Figure 2.11 Molecular weight data for protected and deprotected PEAs.
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Figure 2.12 Size exclusion chromatograms of polymer 2.1 plotted with respect to Log
(molecular weight) prior to degradation, as well as after different time points in the
degradation process (eluent = DMF with 10 mM LiBr and 1% (v/v) NEt3; detection by
differential refractive index).
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Figure 2.13 Size exclusion chromatograms of polymer 2.30 plotted with respect to Log
(molecular weight), prior to degradation, as well as after different time points in the
degradation process (eluent = DMF with 10 mM LiBr and 1% (v/v) NEt3; detection by
differential refractive index).
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2.2.7 Mass loss studies of polymers
The solution degradation properties described above for the PEAs were of interest for
applications in which the PEAs would be present in solution such as in a micellar
carrier.19-20,31 However, there is also substantial interest in the use of PEAs in applications
such as tissue engineering where they would be used as a coating or scaffold material.34-36
Here they offer potential advantages over polyesters, which typically erode via bulk
degradation,1,13 rapidly releasing harmful acidic byproducts.11,12 PEAs have been
proposed to undergo surface erosion mechanisms,13,82-84 which limit the release of acidic
byproducts.14,17-18Although there have been many reports of PEAs degrading in the
presence of enzymes, 71,82-84 their degradation in buffer solution in the absence of specific
enzymes is quite slow.17,22 Therefore, it was of interest to determine how the cleavage of
the pendant side chain protecting groups could trigger the degradation of PEA films via
trigger-initiated cyclization. Polymers 2.1, 2.2, and 2.30 and were melt pressed to form 1
mm thick films, and circular disks, each weighing approximately 5-8 mg, were punched
from these films. In this case, the control polymer 2.31 was also included to investigate
the effect of pendant group incorporation. The films were placed into vials containing pH
7.4 phosphate buffer, along with DTT in the case of polymer 2.2. As preliminary studies
showed that degradation was very slow at 37 C (eg. only 10% mass loss over 2 weeks in
the case of polymer 2.2), the films were incubated at 70°C in order to accelerate
degradation to a more easily measured rate. At various time points, the films were
removed from the buffer solution, washed thoroughly with pure water, and then dried to a
constant mass.
As shown in Figure 2.14, the control polymer 2.31 exhibited only ~10% mass loss
over 8 weeks. In comparison, the Boc protected polymer 2.1 exhibited almost 30% mass
loss over 8 weeks, an enhancement likely attributable to its increased polarity relative to
control 2.31, and/or disruption of solid phase packing of the polymer, allowing enhanced
penetration of water into the film. This has been previously observed by our group for
polymers containing polar pendant groups, even in the absence of cyclization reactions.64
Polymer 2.2 exhibited more than 30% mass loss over 8 weeks, likely due to the
cyclization of the pendant thiols upon cleavage by DTT. The polymer containing pendant
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amines degraded fastest, likely due to the propensity of the amines to cyclize as well as
their high polarity as they would be largely protonated at pH 7.4. As can be seen in
Figure 2.14, the almost linear plot for each polymer suggests a surface erosion
mechanism. This was also supported by SEC analyses as it was found that there were no
measurable changes in the MW characteristics of the polymers comprising the residual
films (see appendix).
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Figure 2.14 Mass loss studies of deprotected and protected polymers.
Scanning electron microscopy (SEM) was performed on the films throughout the
degradation process in order to further investigate the surface erosion process. SEM
images of the films before degradation are shown in Figure 2.15 a-d. The surfaces of the
polymers appear relatively smooth prior to degradation. Following 2 weeks in pH 7.4
phosphate buffer, small pore formation is evident in polymer 2.31 (Figure 2.15e). More
surface erosion is evident for polymer 2.1 (the Boc protected), consistent with the results
of the mass loss studies. Extensive surface erosion was observed for polymers 2.30
(Figure 2.12 h) and 2.2 (Figure 2.12 g), again consistent with the results of the mass loss
studies. Overall, the mass loss, SEC, and SEM studies of these films indicate that as
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designed, these polymers undergo surface erosion processes at rates that are dependent on
the unmasking of the pendant amines or thiols.

Figure 2.15 Scanning electron microscopy images (x500 magnification) of thin films of
polymer (a) 2.31 prior to incubation, (b) 2.1 prior to incubation, (c) 2.30 prior to
incubation, (d) 2.2 prior to incubation, (e) 2.31 following 2 week incubation in PBS (70
°C), (f) 2.1 following 2 week incubation in PBS (70 °C), (g) 2.30 following 2 week
incubation in PBS (70 °C), (h) 2.2 following 2 week incubation in PBS (70 °C).
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2.2.8 Development of photochemically responsive PEA
2.2.8.1 Design
While the specific cleavage of the disulfide bond is possible in vivo in reducing
environments such as within cells or in hypoxic tissues such as tumours,72-74 it should be
noted that there is no method to remove a Boc group under biological conditions. As the
degradation properties of the DAB polymer 2.30 appeared highly promising, an approach
allowing for a more relevant amine unmasking strategy that could eventually be applied
in vivo was sought. Light as a stimulus is attractive because it is non-invasive and can be
applied for a short period of time with high spatial and temporal precision.32 One of the
most widely used groups for these applications is the o-nitrobenzyl moiety, widely
chosen for its clean removal.32,34,37-41 Due to its favorable properties, 4,5-dimethoxy-2nitrobenzyl alcohol was chosen as the photo-labile group for the DAB polymer. Although
the short wavelength of light (~350 nm) required for cleavage of this o-nitrobenzyl group
is not directly applicable in vivo, it would be relatively simple to later extend the
chemistry to moieties that are responsive in the near-infrared range where tissue is much
more transparent.32-36,39

2.2.8.2 Synthesis of a photochemically responsive PEA
The commercially available o-nitrobenzyl alcohol (2.32) was coupled to nitrophenyl
chloroformate under basic conditions and with a catalytic amount of DMAP to afford
2.34 (Scheme 2.11). The target polymer was then formed by coupling the amines of the
deprotected polymer 2.30 to this nitrophenyl carbonate to give the final product, 2.35,
which was purified by dialysis. SEC analysis revealed a unimodal distribution
corresponding to an Mn of 72,200 g/mol and a PDI of 1.41. 1H NMR spectroscopy
verified the incorporation of the o-nitrobenzyl groups onto the polymer backbone and as
can be seen in Figure 2.16 a, a peak at 5.30 ppm corresponding to the benzylic protons
verifies incorporation of the photochemically responsive monomer. Other peaks
corresponding to the dimethoxy nitrobenzyl group also further verify the incorporation.
NMR was also used to determine the time scale needed to remove the dimethoxy
nitrobenzyl moiety. In brief, the polymer was dissolved in the same mixed organic
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solvent mixture (7:2:1 ratio of DMSO: acetone –D6: 0.1 M, pH 7.4 phosphate buffer
D2O) and irradiated with a medium–pressure Hg lamp (λ=350 nm) for different time
periods. It was found that an irradiation time of two hours was sufficient enough to cleave
the photo labile group (Figure 2.16 b).

Scheme 2.11 Synthesis of 4-nitrophenyl carbonate derivative 2.34.

Scheme 2.12 Synthesis of photochemically responsive PEA 2.35.
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Figure 2.16 1H NMR spectra of a) polymer 2.35 in DMSO:acetone–D6: 0.1 M pH 7.4
phosphate buffered D2O b) polymer 2.35 in DMSO:acetone–D6: 0.1 M pH 7.4 phosphate
buffered D2O following 2 hr of irradiation.
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2.2.8.3 Degradation of photochemically responsive PEA
In a similar fashion to the other stimuli responsive PEAs, two samples of polymer 2.35
were dissolved in DMSO:acetone–D6: 0.1 M, pH 7.4 phosphate buffered D2O solvent
system. One sample was irradiated, while the other sample was not subjected to
irradiation. The solutions were incubated at 70°C and aliquots were submitted for SEC
analysis. The changes in Mn and Mw over time are shown in Figure 2.17 and 2.18. Similar
to polymer 2.30, described above, the irradiated sample exhibited a 97% reduction in Mn
during the first ten days. In contrast, the non-irradiated sample exhibited only a 68%
reduction in Mn over the sample time period.
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Figure 2.17 Molecular weight data for non irradiated and irradiated samples.
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Figure 2.18 Molecular weight data for non irradiated and irradiated samples.
As for the polymers described above, it was also of interest to investigate the degradation
of films of polymer 2.35 in the response to photochemical irradiation. In this case, spin
coating rather than melt pressing was used to prepare the films as thinner films were
required to achieve light penetration throughout the film. In order to determine the time
scale required for the irradiation process, UV-visible spectroscopy was undertaken to
determine the decrease in absorbance over time of the characteristic peak corresponding
to the o-nitrobenzyl group.32,34,37 Based on the results shown in Figure 2.19, it was found
that an irradiation time of 1 hour was enough to cleave the photo labile groups in the thin
films. To investigate the thin film degradation in response to the photochemical stimulus,
samples of films were either irradiated, or not, then placed in a pH 7.4 phosphate buffer
solution and incubated at 70 °C. Due to the requirement for thin films, the quantities of
materials were not sufficient for mass loss or SEC measurements, but the film erosion
was investigated by SEM imaging. As shown in Figures 2.20a, the film is smooth prior to
degradation. The non irradiated is intact after 2 days in the buffer solution (Figure 2.17b).
In contrast degradation of the irradiated sample is very rapid, with only small fragments
of the film remaining after 2 days (Figure 2.17c). Based on these SEM results, it is clear
that photochemical cleavage does trigger accelerated degradation relative to the nonirradiated sample, suggesting that these DAB-based polymers are versatile backbones for
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the incorporation of various trigger moieties that can potentially be cleaved under
biologically accessible conditions, leading to stimuli-responsive PEAs.

0.4
0.35

Absorbance

0.3
0.25
Initial run

0.2

Half hour later

0.15

1 hour later

0.1
0.05
0
300

320

340

360

Wavelength (nm)

Figure 2.19 Irradiation of thin films.
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Figure 2.20 Scanning electron microscopy images (x100 magnification) of thin films of
polymer (a) 2.35 prior to irradiation and incubation in PBS (70 °C), (b) 2.35 (non
irradiated), following 24 hr incubation in PBS (70 °C), (c) 2.35 (irradiated), following
24 hr incubation in PBS (70 °C).
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2.3

Conclusions

In conclusion, the first stimuli responsive PEAs were synthesized. This was
accomplished by incorporating monomers with pendant groups capable of cyclization.
Upon cleavage of trigger moieties protecting these pendant groups, in response to stimuli
such as changes in redox potential, acid or light into the backbone, the monomers
underwent 1,5-cyclizations, leading to backbone cleavage and thus degradation of the
PEAs. To support the design, kinetic studies were performed on small molecule models
and they supported the proposed route of degradation via 1,5-cyclization. The polymers
were then synthesized by interfacial polymerization reactions. Polymer degradation
studies were also carried out in solution using SEC analysis and on thin films using mass
loss, SEC, and SEM and these studies suggested that as designed, the polymers could be
cleaved by these 1,5-cyclization reactions more rapidly than the background rate of ester
hydrolysis. In addition, a photoresponsive PEA was synthesized showing that various
triggers could be incorporated, thereby demonstrating the potential for this degradation
mechanism to be applied for biomedical applications. Overall, the results show that the
concepts of self-immolative spacers could be applied to PEAs in order to trigger their
degradation under specified conditions.

2.4

Experimental

General procedures and Materials:
All reagents were purchased from commercial suppliers and used without further
purification unless otherwise noted. Anhydrous DMF and CH2Cl2 were obtained from a
solvent purification system based on aluminum oxide columns. Pyridine and NEt3 were
distilled from CaH2. Unless otherwise stated, all reactions were performed under a N2
atmosphere using flame or oven dried glassware. Column chromatography was
performed using silica gel (0.063-0.200 mm particle size, 70-230 mesh). Thin layer
chromatography was performed using Macherney-Nagel Polygram® SIL G/UV254 plates.
1

H NMR spectra were obtained at 400 or 600 MHz and 13C NMR spectra were obtained

at 100 MHz or 150 MHz using a Varian Mercury or Varian Inova spectrometer. NMR
chemical shifts are reported in ppm and are calibrated against residual solvent signals of
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CDCl3 (δ 7.27, 77), DMSO-d6 (δ 2.50, 40), CD3OD (δ 3.31 49) and D2O (δ 4.79).
Coupling constants (J) are expressed in Hertz (Hz). Infrared spectra were obtained as
films from CH2Cl2 on NaCl plates using a Bruker Tensor 27 instrument. High-resolution
mass spectrometry (HRMS) was performed using a Finnigan MAT 8400 mass
spectrometer using either electron impact (CI) or a Micromass LCT electrospray
ionization time-of-flight (ESI) mass spectrometer Size exclusion chromatography (SEC)
was carried out at a flow rate of 1 mL/min in N,N-dimethylformamide (DMF) with 10
mM LiBr and 1% (v/v) NEt3 at 85 °C using a Waters 2695 separations module equipped
with a Waters 2414 differential refractometer and two PLgel 5 μm mixed-D (300 mm ×
7.5 mm) columns from Polymer Laboratories connected in series. The calibration was
performed using polystyrene standards. Dialysis of the polymers was performed using
Spectra/Por regenerated cellulose membranes with an 8000 - 12,000 g/mol molecular
weight cutoff (MWCO).
Synthesis of compound 2.9: An excess of dry ethanol was added to a flame-dried flask
containing N-α-Fmoc-N-ε-t-Boc-L-2, 4-diaminobutyric acid (1.00 g, 2.27 mmol), N,N’dicyclohexylcarbodiimide (DCC) (0.934 g, 4.53 mmol), 4-(dimethylamino)pyridine
(DMAP) (0.0462 g, 0.378 mmol), and 4-(dimethylamino)pyridinium-4-toluenesulfonate
(DPTS) (0.222, 0.755 mmol), dissolved in distilled CH2Cl2 (30 mL). The solution was
stirred until completion, as measured by TLC (0.5 hr). The reaction mixture was then
diluted with CH2Cl2 and filtered over cotton to remove dicyclohexylurea (DCU). The
solvent was removed and the crude product was then purified via column
chromotography (70:30 cyclohexane:ethyl acetate) to give 0.543 g (1.16 mmol) of
compound 2.9 as a white powder. Yield: 85%. 1H NMR (400 MHz, CDCl3): 7.78 (d, J =
7.4, 2H, Ar-H), 7.62 (d, J= 7.4, 2H, Ar-H), 7.42 (t, J = 7.4, 2H, Ar-H), 7.31-7.35 (m, 2H,
Ar-H), 5.62 (d, J= 7.82, 1H, Fmoc-NH-CαH-), 5.05 (s, 1H, Boc-NH-CH2-), 4.42-4.44 (m,
3H, Ar2-CH-CH2-CO2-NH-CαH-, Ar2-CH-CH2- Boc-NH-), 4.20-4.25 (m, 3H, -CO2-CH2CH3, Boc-NH-(CH2)2-CαH-), 3.33-3.36 (m, 1H, (diastereotopic), -CαH-CH2-CH2-NHBoc), 2.97-3.01 (m, 1H, (diastereotopic), -CαH-CH2-CH2-NH-Boc), 2.08-2.09 (m, 1H,
(diastereotopic), -CαH-CH2-CH2-NH-Boc), 1.76-1.78 (m, 1H, (diastereotopic), -CαHCH2-CH2-NH-Boc), 1.46 (s, 9H, Boc), 1.30 (t, J= 7.03, 3H, -CO2-CH2-CH3-). 13C NMR
(CDCl3): δ 172.23, 156.37, 143.82, 141.30 127.73, 127.08, 125.06, 120.00, 79.35, 67.03,
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61.73, 51.53, 47.17, 36.49, 33.27, 28.42, 14.14. IR (cm-1): 3345, 2977, 2933, 1711, 1521,
1510, 1045, 1168. HRMS: calc [M]+ (C26H32N2O6): 468.2260 Found: (CI) 468.2237.
Synthesis of compound 2.3: Compound 2.5 (0.314 g, 0.670 mmol) was dissolved in
tetrahydrofuran (THF) (4.0 mL). To this was added 1-octanethiol (1.16 mL, 6.70 mmol)
and 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU) (0.010 mL, 67.0 µmol). The solution
was stirred for 3 hr, and then the solvent was removed. The crude mixture was purified
via column chromatography (70:25:5 ethyl acetate:cyclohexane:triethylamine), affording
0.132 g (0.536 mmol) of compound 2.6 as a slightly yellow oil. Yield: 80%. 1H NMR
(400 MHz, D2O): 4.13 (q, J= 7.03, 2H, -CO2-CH2-CH3), 3.46-3.51 (m, 1H, -CαH-(CH2)2NH-Boc), 3.09-3.14 (m, 2H, -CαH-CH2-CH2-NH-Boc), 1.77-1.84 (m, 2H, -CαH-CH2CH2-NH-Boc), 1.35 (s, 9H, Boc), 1.21 (t, J= 7.03, 3H, -CO2-CH2-CH3). 13C NMR
(CDCl3): 175.32, 155.60, 78.73, 60.67, 52.57, 37.49, 34.03, 28.02, 13.81. IR (cm-1):
3374, 2978, 1711, 1251, 1027, 1174, 781. HRMS: calc [M]+ (C11H22N2O4): 246.1580
Found: (CI) 247.1650
Synthesis of compound 2.11: NaHCO3 (8.19 g, 97.5 mmol) was placed in a 1:1 mixture
of H2O:dioxane (100 mL). To this stirring solution, DL-homocysteine thiolactone·HCl
(5.00 g, 32.5 mmol) was added over a period of 30 min. Finally, di-tert-butyl dicarbonate
(10.64 g, 48.75 mmol) was added and the reaction mixture was stirred overnight. The
reaction mixture was then diluted with ethyl acetate, washed twice with saturated
NaHCO3, and then twice with brine. The organic phase was dried over MgSO4, filtered,
and the solvent was removed to yield 8.69 g (36.9 mmol) compound 2.11 as a white solid.
Characterization data agreed with that previously reported in the literature.85
Synthesis of compound 2.12: To a stirring solution of LiOH (3.0 g, 71.3 mmol) in a 1:1
mixture of H2O:THF (90 mL) was added compound 2.11 (5.50 g, 23.8 mmol). The
solution was stirred until the reaction was complete (3 hr) as detected by TLC. The
solution was then diluted with ethyl acetate and washed three times with 1 M HCl. The
organic phase was then dried over MgSO4, filtered, and the solvent was removed to give
5.03 grams (21.4 mmol) of 2.12 as an amber colored oil. Yield: 90%. 1H NMR (400
MHz, CD3OD): 4.89 (s, 1 H, -NH-Boc-CαH -CO2H), 4.23-4.26 (m, 1H, -CαH -CO2H),
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2.48- 2.58 (m, 2H, -CαH-CH2-CH2-), 1.89-2.02 (m, 2H, -CαH-CH2-CH2-), 1.41 (s, 9H,
Boc). 13C NMR (CD3OD): δ 175.90, 158.24, 80.68, 53.53, 37.27, 28.85, 21.71. IR (cm-1):
IR (cm-1): 3361, 2925, 2867, 1656, 1510. HRMS: calc [M]+ (C9H17NO4 S1): 235.0878
Found: (CI) 236. 0950.
Synthesis of compound 2.14: 2 2’-Dipyridyl disulfide, 2.13 (9.56 g, 43.4 mmol) was
dissolved in methanol (53 mL) and acetic acid (0.71 mL). To this, compound 2.12 (5.11
g, 21.7 mmol) dissolved in methanol (10.0 mL) was added dropwise via an addition
funnel. The solution was stirred until reaction completion as determined by NMR (3 hr).
The reaction mixture was then diluted with ethyl acetate and washed 3 times with 0.5 M
pH 5 citrate buffer. The organic phase was dried over MgSO4, filtered, and the solvent
was removed in vacuo. The crude product was purified with column chromotography
(70:30 cyclohexane:ethyl acetate, then 60:40 cyclohexane:ethyl acetate), yielding 4.27 g
(12.4 mmol) of compound 2.14 as a white powder. Yield: 57%. 1H NMR (400 MHz,
CDCl3): 8.51-8.52 (m, 2H, Ar-H), 7.78-7.80 (m, 1H, Ar-H), 7.70-7.72 (m, 1H, Ar-H),
7.15-7.18 (m, 1H, Ar-H), 5.45-5.47 (s, 1H, Boc-NH-), 4.45-4.46 ( m, 2H, -NH-CαHCO2H-), 2.85-2.90 (m, 2H, -CαH-CH2-CH2-S-S-), 2.39 ( s, 1H, (diastereotopic), -CαHCH2-CH2-S-S-), 2.05-2.10 (m, 1H, (diastereotopic), -CαH-CH2-CH2-S-S-), 1.44 (s, 9H,
Boc). 13C NMR (CDCl3): δ 175.13, 160.11, 155.94, 149.11, 138.18, 121.36, 120.88,
80.38, 52.75, 35.12, 32.50, 28.57. IR (cm-1): 3356, 2978, 2932, 1712, 1574, 1518, 1250,
1120, 510. HRMS: calc [M]+ (C14H20N2O4 S2): 244.0864 Found: (CI) 244.0334.
Synthesis of compound 2.15: An excess of dry ethanol was added to a flame-dried flask
containing 2.14 (0.700 g, 2.03 mmol), DCC (1.05 g, 5.07 mmol), DMAP (0.0517 g, 0.423
mmol), and DPTS (0.249 g, 0.845 mmol) dissolved in distilled CH2Cl2 (20 mL). The
solution was stirred until completion by TLC (1.5 hr). The reaction mixture was then
diluted with CH2Cl2 and filtered over cotton to remove DCU. The solvent was removed,
and the crude product was then purified via column chromotography (60:40 cyclohexane:
ethyl acetate) to give 0.502 g (1.35 mmol)of compound 2.15 as a clear, pale green oil.
Yield: 80%. 1H NMR (400 MHz CDCl3): 8.46-8.49 (m, 1H, Ar-H), 7.64-7.67 (m, 2H, ArH), 7.08-7.12 (m, 1H, Ar-H), 5.28 (s, 1H, Boc-NH-CαH-CO2-), 4.38-4.39 (m, 1H, -NHCαH-CO2-CH2-), 4.11-4.20 (m, 2H, -CO2-CH2-CH2-), 2.82-2.88 (m, 2H, -CαH-CH2-
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CH2-S-S-), 2.25-2.28 (m, 1H, (diastereotopic), -CαH-CH2-CH2-S-S-), 2.00-2.06 (m, 1H,
(diastereotopic), -CαH-CH2-CH2-S-S-), 1.43 (s, 9H, Boc),1.24 ( t, 3H, J =7.23, -CO2CH2-CH3). 13C NMR (CDCl3): δ 172.33, 160.14, 155.68, 149.97, 137.29, 121.01, 120.11,
80.29, 61.86, 52.92, 35.07, 32.49, 28.57, 14.41. IR (cm-1): 3356, 2978, 2932, 1712, 1574,
1518, 1250, 1118, 500. HRMS: calc [M+H]+ (C16H24N2O4 S2): 373. 1257 Found: (CI)
373. 0734.
Synthesis of compound 2.4: Compound 2.15 (0.115 g, 0.309 mmol) was dissolved in a
1:1 mixture of TFA:CH2Cl2 and stirred for 2 hr. The solvent was then removed to give
compound 2.4 as a slightly yellow oil in quantitative yield. 1H NMR (400 MHz D2O):
8.31-8.33 (m, 1H, Ar-H), 7.67-7.74 (m, 2H, Ar-H), 7.21-7.23 (m, 1H, Ar-H), 4.14-4.18
(m, 3H, -CO2-CH2-CH3-, -NH-CαH- CO2-CH2), 2.85-2.87 (m, 2H, -CαH-CH2-CH2-S-S), 2.23-2.25 (m, 2H, -CαH-CH2-CH2-S-S-), 1.09-1.13 (t, J=7.23, 3H, -CO2-CH2-CH3-).
13

C NMR (CD3OD): δ 170.11, 160.36, 150.33, 139.81, 122.29, 122.09, 63.97, 52.90,

34.87, 30.85, 14.42. IR (cm-1): 3443, 1636, 1204, 1258, 723. HRMS: calc [M+H]+
(C11H16N2O2 S2): 273. 0733 Found: (CI) 273. 0734.
Synthesis of 2.25:1,4-butanediol (0.160 mL, 1.82 mmol), was added to a flame-dried
flask containing DAB (2.00 g, 4.54 mmol), DCC (1.13 g, 5.46 mmol), DMAP (0.0556 g,
0.455 mmol), and DPTS (0.134, 0.455 mmol), dissolved in distilled CH2Cl2 (40 mL).
The solution was stirred until completion by TLC (0.5 hr). The reaction mixture was then
diluted with CH2Cl2 and filtered over cotton to remove DCU. The solvent was removed,
and the crude product was then purified via column chromotography (70:30cyclohexane:
ethyl acetate, then 60:40cyclohexane: ethyl acetate) to give 1.37 g (1.46 mmol) of
compound 2.25 as a white powder. Yield: 80%.1H NMR (400 MHz CDCl3): 7.78 (d, J=
7.42, 4H, Ar-H), 7.61 (d, J= 7.42, 4H, Ar-H), 7.41 (t, J= 7.42, 4H, Ar-H), 7.33 (m, 4H,
Ar-H), 5.68 (d, J= 7.82, 2H Fmoc-NH-CαH-), 5.10 (s, 2H, Boc-NH-CH2-), 4.40-4.46 (m,
6H, Ar2-CH-CH2-CO2-NH-CαH and Ar2-CH-CH2-Boc-NH-), 4.12-4.18 (m, 6H, -CO2CH2-CH3 and Boc-NH-(CH2)2-CαH-), 3.36-3.39 (m, 2H, (diastereotopic), -CαH-CH2CH2-NH-Boc), 2.97-3.01 (m, 2H, (diastereotopic), -CαH-CH2-CH2-NH-Boc), 2.03-2.09
(m, 2H, (diastereotopic), -CαH-CH2-CH2-NH-Boc), 1.73 (m, 2H, (diastereotopic), -CαHCH2-CH2-NH-Boc, 4H, CO2-CH2-CH2-), 1.46 (s, 18H, Boc). 13C NMR (CDCl3): δ
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172.28, 156.39, 143.81, 141.29, 127.73, 125.06, 120.00, 79.40, 67.06, 64.93, 51.53,
47.15, 36.53, 33.94, 28.42, 25.07. IR (cm-1): 3245, 2987, 2953, 1741, 1532, 1510, 1218,
1066, 1200. HRMS: calc [M]+ (C51H60N4O12):934.4364 Found: (ESI) 934. 4364.
Synthesis of compound 2.26: Compound 2.26 (0.285 g, 0.305 mmol) was dissolved in 4
mL of THF. To this was added 1-octanethiol (0.529 mL, 3.05 mmol) and DBU (0.0456
µL, 0.0148 µmol). The reaction was stirred for 3hr, and then the solvent was removed.
The crude mixture was then redissolved in chloroform, then precipitated from a cold
solution of hexanes (20 mL), affording 0.0633 g of compound 2.26 as a yellow gel 0.105
g (0.214 mmol). Yield: 70%. The product was carried on towards the next step without
further purification. 1H NMR (400 MHz CDCl3): 5.19 (br s, 2H, Boc-NH-(CH2)2-CαH),
4.15 (s, 4H, -CO2-CH2-CH3), 3.48 (br s, 2H, -CαH-CH2-CH2-NH-Boc) 3.35-3.37 (m, 2H,
(diastereotopic),-CαH-CH2-CH2-NH-Boc), 3.22-3.25 (m, 2H, (diastereotopic), -CαHCH2-CH2-NH-Boc), 1.94-1.97 (m, 2H, (diastereotopic), -CαH-CH2-CH2-NH-Boc), 1.44
(s, 18H, Boc).
Synthesis of compound 2.27: 1,4-butanediol (0.103 mL, 1.16 mmol), was added to a
flame-dried flask containing 2.14 (1.00 g, 2.90 mmol), DCC (0.718 g, 3.48 mmol),
DMAP (0.0354 g, 0.290 mmol), and DPTS (0.170 g, 0.580 mmol), dissolved in distilled
CH2Cl2 (15 mL). The solution was stirred until completion by TLC (2.0 hr). The reaction
mixture was then diluted with CH2Cl2 and filtered over cotton to remove DCU. The
solvent was removed, and the crude product was then purified via column
chromotography (60:40cyclohexane: ethyl acetate, then 50:50cyclohexane: ethyl acetate)
to give 0.689 g (0.928 mmol) of compound 2.27 as a cloudy, pale green gel. Yield: 80%.
1

H NMR (400 MHz CDCl3): 8.47-8.49 (m, 2H, Ar-H), 7.62-7.68 (m, 4H, Ar-H), 7.08-

7.10 (m, 2H, Ar-H), 5.40 (s, 2H, Boc-NH-CαH-CO2-), 4.39-4.40 (m, 2H, -NH-CαH-CO2CH2-), 4.12 (s, 4H, -CO2-CH2-CH2-), 2.83-2.88 (m, 4H, -CαH-CH2-CH2-S-S-), 2.27-2.29
(m, 2H, (diastereotopic), -CαH-CH2-CH2-S-S-), 2.02-2.06 (m, 2H, (diastereotopic), CαH-CH2-CH2-S-S-), 1.43 (s, 18H, Boc). 13C NMR (CDCl3): δ 172.29, 159.98, 155.66,
149.91, 137.28, 121.00, 120.05, 80.25, 65.04, 52.87, 5.01, 32.21, 28.54, 25.29. IR (cm-1):
3374, 2977, 2965, 1712, 1520, 1576, 1049, 1166, 510. HRMS: calc [M]+ (C32H46N4O8
S4): 742.2198 Found: (ESI) 742. 2198.
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Synthesis of compound 2.28: Compound 2.28 (0.200 g, 0.268 mmol) was dissolved in a
1:1 mixture of TFA:CH2Cl2 and stirred for two hours. The solvent was then removed to
give compound 2.28 as a yellow viscous oil in quantitative yield. 1H NMR (400 MHz
CD3OD): 8.44-8.45 (m, 2H, Ar-H), 7.81-7.83 (m, 4H, Ar-H), 7.26-7.29 (m, 2H, Ar-H),
4.23- 4.30 (m, 1H, -NH-CαH-CO2-CH2-, 4H, -CO2-CH2-CH2-), 2.96-3.01 (m, 4H, -CαHCH2-CH2-S-S-), 2.31-2.40 (m, 4H, -CαH-CH2-CH2-S-S-), 1.71-1.73 (br s, 4H, -CO2-CH2CH2-). 13C NMR (CD3OD): δ 169.96, 159.88, 149.56, 140.34, 123.05, 122.30, 67.03,
52.66, 34.72, 30.63, 25.88. IR (cm-1): 3443, 1636, 1204, 1142, 723. HRMS: calc [M]+
(C22H30N4O4 S4): 542. 1150 Found: (ESI) 542. 1150.
Synthesis of compound 2.34: Freshly distilled N,N-diisopropylethylamine (DIPEA)
(0.0113 mL, 11.3 mmol) was added slowly to a reaction flask containing the nitrobenzyl
alcohol 2.32 (2.00 g, 9.38 mmol) and 4-nitrophenyl chloroformate (2.28 g, 11.3 mmol) in
distilled CH2Cl2 (94 mL) . The solution was stirred until the reaction was complete as
determined by thin layer chromatography (3 hr). The solution was then diluted with
CH2Cl2 and washed with 1 M HCl, then with 1M NaHCO3. The organic phase was dried
over MgSO4, filtered, and the solvent was removed in vacuo. The crude product was
purified with column chromatography (80:20cyclohexane: ethyl acetate, then
60:40cyclohexane: ethyl acetate), yielding 2.34 (1.70 g, 4.50 mmol) as an off white
powder. Yield: 48 %. 1H NMR (400 MHz CDCl3): 8.30-8.32 (m, 2H, Ar-H), 7.78 (s, 1H,
Ar-H), 7.41-7.44 (m, 2H, Ar-H), 7.12 (s, 1H, Ar-H), 5.72 (s, 2H, Ph-CH2-CO2-Ph), 4.04.04 (s, 9H, CH3-Ph). 13C NMR (CDCl3): δ 154.97, 153.32, 151.68, 148.42, 145.14,
139.62, 124.98, 121.35, 110.26, 108.01, 67.30, 56. 20. HRMS: calc [M]+ (C16H14N2O9):
378.0699 Found: (CI) 378.0699.
Synthesis of polymer 2.1: The di-p-toluenesulfonic acid salt monomer 2.29, whose
synthesis has been previously reported elsewhere,80 (1.71g, 2.35 mmol) and sodium
carbonate (0.654 g, 6.17 mmol) were dissolved in distilled water (20 mL). Diester 2.26
(0.288 g, 0.587 mmol) was dissolved in dichloromethane (20 mL) and added to the
aqueous phase and allowed to mix for 30 min. Sebacoyl chloride (0.628 mL, 2.94 mmol)
diluted in anhydrous dichloromethane (5 mL), was added drop wise over 30 min to the
biphasic solution and was allowed to react for 24 hr. Upon completion of the reaction,
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solvent was removed in vacuo. The resulting polymer was redissolved in DMF,
permitting filtration of the insoluble salts. The filtrate was then dialysed against DMF for
24 hrs, with at least one dialysate change over this time period. The purified PEA was
precipitated in water (5 mL) and lyophilized for 24 hrs to give an off white solid (1.31 g,
1.91 mmol). Yield: 65%. 1H NMR (600 MHz DMSO): 8.22 (d, J= 7.63, 1.6H, -CO-NHCαH-CH2-Ph), 8.13 (d, J=7.63, 0.4H, -CO-NH-CαH-CO2-), 7.17-7.26 (m, 8H, Ph) 6.78 (s,
0.4H, Boc-NH-(CH2)2-CαH-), 4.43-4.47 (m, 1.6H, -CO-NH-CαH-CH2-Ph), 4.18-4.21 (m,
0.4H, Boc-NH-(CH2)2-CαH-), 4.03(s, 0.8H, Boc-NH-(CH2)2-CαH-CO2-CH2-), 3.96 (s,
1.6H, Ph-CH2-CαH-CO2-CH2-), 2.87-3.01 (m, 4H, -CαH-CH2-Ph, -CαH-CH2-CH2-NHBoc), 2.09 (b s, 0.8H, -NH-CO-CH2-), 2.02-2.04 (m, 3.2H, -NH-CO2-CH2-), 1.83-1.84
(m,

0.4H,

(diastereotopic),

-CαH-CH2-CH2-NH-Boc),

1.63-1.69

(m,

0.4H,

(diastereotopic), -CαH-CH2-CH2-NH-Boc), 1.60 (s, 0.8H, -CO2-CH2-CH2-), 1.43 (b s,
3.2H, -CO2-CH2-CH2-), 1.36 (b s, 3.2H, -NH-CO-CH2-CH2-), 1.32 (s, 3.6H, Boc), 1.20 (b
s, 0.8H, -NH-CO-CH2-CH2-), 1.11 (b s, 8H, -NH-CO-CH2-CH2-CH2-, -NH-CO-CH2CH2-CH2-CH2-). IR (cm-1): 3442, 2930, 2875, 1647, 1523, 1180, 1201, 700. SEC: Mn
=155,500; Mw = 126,400; PDI = 1.23.
Synthesis of polymer 2.2: The di-p-toluenesulfonic acid salt monomer 2.29,80 (3.85 g,
5.28 mmol) and sodium carbonate (1.47 g, 13.9 mmol) were dissolved in distilled water
(33 mL). Diester 2.28 (1.02 g, 1.32 mmol) was dissolved in mixture containing
dichloromethane (23 mL) and THF (2 mL), then added to the aqueous phase and allowed
to mix for 30 min.

Sebacoyl chloride (1.41 mL, 6.6 mmol) diluted in anhydrous

dichloromethane (8 mL), was added drop wise over 30 min to the biphasic solution and
was allowed to react for 24 hr. Upon completion of the reaction, solvent was removed in
vacuo. The resulting polymer was purified as described above for polymer 2.2 to give an
off-white solid (2.34 g, 3.3 mmol). Yield: 50 %. 1H NMR (600 MHz DMSO): 8.47-8.49
(s, 0.4H, Ar-H) 8.23 (d, J= 7.63, 1.6H, -CO-NH-CαH-CH2-Ph), 7.72-7.79 (m, 0.4H, ArH), 7.17-7.26 (m, 8.4H, Ph, Ar-H), 4.43-4.47 (m, 1.6H, -CO-NH-CαH-CH2-Ph), 4.384.39 (m, 0.4H, Pyr-S-S-(CH2)2-CαH-), 3.96 (s, 4H, Pyr-S-S-(CH2)2-CαH-CO2-CH2-, PhCH2-CαH-CO2-CH2-), 2.87-3.01 (m, 4H, -CαH-CH2-Ph, Pyr-S-S-CH2-CH2-), 2.162.17(m, 0.4H, (diastereotopic), Pyr-S-S-CH2-CH2-), 2.07 (m, 0.8H, -NH-CO2-CH2-),
2.02-2.04 (m, 3.2H, -NH-CO-CH2-), 1.94-1.98 (m, 0.4H, diastereotopic (Pyr-S-S-CH2-
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CH2-), 1.52 (s, 0.8H, -CO2-CH2-CH2-), 1.44 (b s, 3.2H, -CO2-CH2-CH2-), 1.36 (b s, 4H, NH-CO-CH2-CH2-, -NH-CO-CH2-CH2), 1.11 (s, 8H, -NH-CO-CH2-CH2-CH2-, -NH-COCH2-CH2-CH2-CH2-). IR (cm-1): 3443, 2926, 2850, 1644, 1455, 1510, 1180, 1200, 700.
SEC: Mn = 98,300; Mw = 79,300; PDI = 1.24.
Synthesis of compound 2.30: Compound 2.1 (0.300g, 0.457 mmol) was dissolved in a
1:1 mixture of TFA:CH2Cl2 and stirred for 2 hr. The solvent was then removed to give
compound 2.30 as slightly brown oil in quantitative yield. The polymer was precipitated
into cold water yielding polymer 2.30 as a white solid (2.35 g, 3.43 mmol). Yield: 75%.
1

H NMR (400 MHz DMSO): 8.19 (s, 1.6H, -CO-NH-CαH-CH2-Ph), 7.15-7.19 (m, 8H,

Ph), 4.43-4.47 (m, 1.6H, CO-NH-CαH-CH2-Ph), 4.30-4.33 (m, 0.4H, Boc-NH-(CH2)2CαH-), 4.04 (s, 0.8H, Boc-NH-(CH2)2-CαH-CO2-CH2-), 3.92 (s, 1.6H, Ph-CH2-CαH-CO2CH2-), 2.87-3.01 (m, 4H, -CαH-CH2-Ph, -CαH-CH2-CH2-NH3+TFA-), 2.10 (b s, 0.8H, NH-CO-CH2-), 2.02-2.04 (m, 3.2H, -NH-CO-CH2-), 1.87-1.90 (m, 0.8H, -CαH-CH2CH2-NH3+TFA-), 1.60 (s, 0.8H, -CO2-CH2-CH2-), 1.42 (b s, 3.2H, -CO2-CH2-CH2-), 1.34
(b s, 3.2H, -NH-CO-CH2-CH2), 1.20 (b s, 0.8H, -NH-CO-CH2-CH2-), 1.11 (b s, 8H, -NHCO-CH2-CH2-CH2-, -NH-CO-CH2-CH2-CH2-CH2-). SEC: Mn =91, 800; Mw = 75, 400
PDI = 1.22
Synthesis of compound 2.35: Compound 2.34 (0.503 g, 1.33 mmol) and DMAP (0.121
g, 0.998 mmol) was dissolved in a mixture containing toluene (4 mL) and CH2Cl2 (7
mL). To this reaction flask was added 2.30 (0.384 g, 0.562) dissolved in CH2Cl2 (5 mL),
then freshly distilled DIPEA (2 mL, 9.98 mmol).The reaction mixture was then stirred for
3 days. The solution was then diluted with CH2Cl2 and washed with 1 M HCl, then with 1
M NaHCO3.The organic layer was dried over MgSO4, filtered, and the solvent was
removed in vacuo. The resulting polymer was purified as described above for polymer
2.1 and 2.2 to give an amber colored solid The purified PEA was precipitated in water (5
mL) and lyophilized for 24 hrs to an amber colored solid (0.229 g, 0.253 mmol). Yield:
45%. 1H NMR (400 MHz DMSO): 8. 23 (d, J= 7.80, 1.6H, -CO-NH-CαH-CH2-Ph), 8.16
(d, J=7.63, 0.4H, -CO-NH-CαH-CO2-), 7.67 (s, 0.4H, Ar-H), 7.47 (s, 0.4H, -CO2-NH(CH2)2-), 7.16-7.25 (m, 8.4H, Ph, Ar-H), 5.31 (s, 0.8H, Ar-CH2-CO2-NH-) 4.42-4.48 (m,
1.6H, -CO-NH-CαH-CH2-Ph), 4.21-4.24 (m, 0.4H, -CH2-CO2-NH-(CH2)2-CαH-), 4.03 (s,
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0.8H, -NH-(CH2)2-CαH-CO2-CH2-), 3.96 (s, 1.6H, Ph-CH2-CαH-CO2-CH2-), 3.88 (s,
1.2H, CH3-O-Ar), 3.84 (s, 1.2H, CH3-O-Ar), 3.03-3.06 (m, 0.8H, -CαH-CH2-CH2-NHCO2-CH2-Ar), 2.87-3.01 (m, 3.2H, -CαH-CH2-Ph), 2.08 (m, 0.8H, -NH-CO-CH2-), 2.022.04 (m, 3.2H, -NH-CO-CH2-), 1.81-1.87 (m, 0.4H, (diastereotopic), -CαH-CH2-CH2NH-CO2-CH2-Ar), 1.71-1.77 (m, 0.4H, (diastereotopic), -CαH-CH2-CH2-NH-CO2-CH2Ar), 1.58 (s, 0.8H, -CO2-CH2-CH2-), 1.44-1.45 (m, 3.2H, -CO2-CH2-CH2-), 1.35-1.39 (m,
3.2H, -NH-CO-CH2-CH2), 1.11 (b s, 8H, -NH-CO-CH2-CH2-CH2-, -NH-CO-CH2-CH2CH2-CH2-). SEC: Mn =72, 200; Mw = 101, 900; PDI = 1.41.
Small molecule compound cyclization studies. In the case of compound 2.3, the Boc
group was removed by placing the compound in a 1:1 ratio of TFA:CH2Cl2. Compounds
2.3, 2.4 were dissolved in either pH 7.4 phosphate buffered D2O or 7:2:1 ratio of DMSO:
acetone –D6: 0.1 M, pH 7.4phosphate buffer D2O. For compounds 2.16 and 2.4, the pH
was readjusted to 7.4 to account for the addition of any acid in the form of TFA salts. In
the case of compound 2.4, DTT (10 mg, 0.0648 mmol) was added. The samples were
then incubated in a sand bath and 1H NMR spectra were obtained at regular intervals. The
degree of ethanol evolution was calculated based on the relative integrations of the peaks
corresponding to the methyl group of ethanol and that of the ethyl ester. First order rate
constants were determined as the slope of ln (percent remaining) vs. time (hr) and the
corresponding half lives were calculated as t1/2= ln(2)/ k
Polymer degradation studies in solution. Polymers 2.1, 2.2, and 2.31 were dissolved in
7:2:1 ratio of DMSO: acetone –D6: 0.1 M pH 7.4 phosphate buffer D2O and incubated in
a 70° C oven for two weeks. Aliquots were taken and were lyophilized for at least 24 hr,
then redissolved in DMF eluent and submitted for SEC analysis
Polymer film degradation studies. Polymers 2.1, 2.2, 2.30 and 2.31 were melt pressed
using a Carver 3851c two post hydraulic press at 500 psi and 45 °C. The samples were
then immersed in a 1 mL solution of phosphate buffer (pH=7.4), for a period of 8 weeks.
For polymer 2.2, 5 mg of DTT was added. Samples were then taken out periodically,
washed thoroughly in order to remove any salts, then lyophilized for 24 hr. In the case of
polymer 2.35, the polymer was first dissolved at a concentration of 20 mg/mL, then an
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aliquot (10 μL) was deposited onto a glass cover slip using a Laurell WS-400Bz-6NPPLite spin coater, operating at 2300 RPM for 10 seconds. The thickness of the spin coated
polymers was measured using a KLA Tensor P-10 profiler equipped with a tungsten
stylus with a diamond on the tip. The applied force was 3 mg and scan speed was 200
μm/s. The average thickness of the films was found to be 221.23 nm. Irradiation was
performed using a medium-pressure mercury lamp (Hanovia S9 PC451050/805221). UVvisible spectroscopy experiments were carried out using a Varian Cary 300 Bio UVvisible spectrophotometer. In all cases, all polymers were mounted on aluminum stubs
with carbon tape (or adhesive for polymer 2.35), then sputter coated with gold. The
surface microstructure was then imaged by scanning electron microscopy (SEM) (S2600N, Hitachi, Japan).
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Chapter 3
Conclusions
3.1

Concluding remarks and future directions

The ability to trigger the degradation of a polymer is attractive for many biological
applications. For example, in the area of drug delivery, a polymeric system may circulate
without decomposing and thus retain its therapeutic efficacy. However, once this polymer
encounters a stimulus that triggers its degradation, it can release its payload to a specific
part of the body, rather than unloading it in undesirable locations such as the heart, or the
liver.
To this end, this thesis described the development of the first stimuli responsive
PEAs. This was accomplished by combining the principles of self-immolative spacers
and PEAs containing functional pendant groups, by incorporating monomers that are
capable of 1,5-cyclization reactions into the PEA backbone. In addition, these spacers
contain protecting groups sensitive to external stimuli such as light or changes in pH or
redox potential, such that once cleavage occurs; the functional moiety is revealed and
induces the degradation of the PEA backbone. Kinetic studies on aliphatic esters indicate
that the degradation of an ester containing these spacers is accelerated, as opposed to
those that do not contain it, thereby supporting the mechanism of degradation.
The polymers were synthesized and subjected to degradation studies. It was found
that even in an organic solution, the polymers containing the self-immolative spacers
degraded faster than their control counter-parts. In addition, studies were carried out on
thin films and the result was the same; the polymers containing the self-immolative
spacers exhibited more mass loss and exhibited more surface erosion than their control
counterparts. The mass loss study results are attractive in that there have not been too
many studies of PEAs in neutral conditions only, as most of them have been undertaken
in the presence of enzymes, whose presence in physiological environments require
special conditions. 1 Also, since the mass loss was gradual, this could be applied to drug
delivery applications, as sustained release is attractive in these studies.
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As well as synthesizing polymers sensitive to changes in pH and redox potential,
a polymer that was sensitive to light was also synthesized. Since the Boc group cannot be
cleaved under physiological conditions, a protecting group sensitive to light was chosen
due to its ability to be applicable to biological applications. The polymer was subjected to
the same degradation conditions as the other polymers (in addition to being irradiated)
and it was found that compared to its control counter part (non irradiated), the polymer
degraded faster. The polymers were then cast into films in order to determine if the
results were applicable on the surface, as well. The polymer that was irradiated exhibited
more surface erosion than its control, which was not irradiated. This study not only shows
that degradation containing these spacers is accelerated; it also exhibits the robustness of
the PEA backbone, able to incorporate different functional groups such that degradation
can be done via different stimuli.
Due to their ability to exhibit triggered degradation and subsequently to degrade
over time (as seen with the mass loss studies), these PEAs are attractive as drug delivery
vehicles. They can potentially release the drug once the stimulus is applied and can
release it over time due to their sustained release. However, work needs to be done to
make these polymers more hydrophilic as they are quite hydrophobic. This could be
circumvented by replacing the diol with ethylene glycol,2 or by attaching a hydrophilic
chain to the pendant functional group, as has been previously reported by our group to
make self-assemblies.3 Also, since the PEA backbone is able to incorporate different
monomers, different ratios of different monomers containing different protecting groups
could be synthesized, such that the polymer is multi responsive to different stimuli.4,5,6
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Figure A.1 First order plot of 2.16 monomer degradation.
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Figure A.2 First order plot of 2.17 monomer degradation.
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Figure A.3 First order plot of 2.3 monomer control.
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Figure A.4 First order plot of 2.17, without DTT.
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Figure A.5 1H NMR (400 MHz) spectra in pH 7.4 phosphate buffered D2O of a) DAB
derivative 2.3 immediately following dissolution in the buffer. b) After 34.5 hr in the
same buffer. c) After 70 hr in the same buffer.
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Figure A.6 1H (400 MHz) NMR spectra in pH 7.4 phosphate buffered D2O of a) Hcy
derivative 2.4 immediately following dissolution in the buffer. b) After 16 hr in the same
buffer. c) After 75 hr in the same buffer.
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Figure A.7 1H NMR (400 MHz) spectra in pH 7.4 phosphate buffered D2O of DAB
amino acid.

Figure A.8 1H NMR (400 MHz) spectra in pH 7.4 phosphate buffered D2O of Hcy amino
acid.
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Figure A.9 1H NMR (400 MHz) spectra in D2O of DAB amino acid prior to degradation.

Figure A.10 1H NMR (400 MHz) spectra in D2O of Hcy amino acid prior to DTT
cleavage.
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Figure A.11 1H (400 MHz) NMR spectra in 7:2:1 ratio of DMSO: acetone –D6: 0.1 M,
pH 7.4 phosphate buffered D2O of compound a) DAB derivative 2.16 immediately
following dissolution. b) After 2 days in the same solution. c) After 8 days in the same
solution.
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Figure A.12 1H (400 MHz) NMR spectra in 7:2:1 ratio of DMSO: acetone –D6: 0.1 M,
pH 7.4 phosphate buffered D2O of compound a) DAB derivative 2.3 immediately
following dissolution. b) After 21 days in the same solution. c) After 46 days in the same
solution.
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Figure A.13 1H (400 MHz) NMR spectra in 7:2:1 ratio of DMSO: acetone –D6: 0.1 M,
pH 7.4 phosphate buffered D2O of compound a) Hcy derivative 2.17 immediately
following dissolution. b) After 8 days in the same solution. c) After 39 days in the same
solution.
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Figure A.14 1H (400 MHz) NMR spectra in 7:2:1 ratio of DMSO: acetone –D6: 0.1 M,
pH 7.4 phosphate buffered D2O of compound a) Polymer 2.1 immediately following
dissolution. b) After 2 weeks in the same solution.
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Figure A.15 1H (400 MHz) NMR spectra in 7:2:1 ratio of DMSO: acetone –D6: 0.1 M,
pH 7.4 phosphate buffered D2O of compound a) Polymer 2.30 immediately following
dissolution. b) After 2 weeks in the same solution.
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Figure A.16 1H (400 MHz) NMR spectra in 7:2:1 ratio of DMSO: acetone –D6: 0.1 M,
pH 7.4 phosphate buffered D2O of compound a) Polymer 2.2 immediately following
dissolution. b) After 2 weeks in the same solution.
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Figure A.17 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra of compound 2.9 in
CDCl3.
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Figure A.18 1H NMR (400 MHz) in D2O and 13C NMR (100 MHz) spectra of compound
2.3 in CDCl3.
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Figure A.19 1H NMR (400 MHz) and 13C NMR (150 MHz) spectra of compound 2.12 in
CD3OD.
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Figure A.20 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra of compound 2.14 in
CDCl3.
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Figure A.21 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra of compound 2.15 in
CDCl3.
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Figure A.22 1H NMR (400 MHz) in D2O and 13C NMR (150 MHz) spectra of compound
2.4 in CD3OD.
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Figure A.23 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra of compound 2.26 in
CDCl3.
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Figure A.24 1H NMR (400 MHz) of compound 2.27 in CDCl3.
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Figure A.25 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra of compound 2.28 in
CDCl3.
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Figure A.26 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra of compound 2.29 in
CD3OD.
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Figure A.27 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra of compound 2.34.
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Figure A.28 SEC chromatogram of melt-pressed polymer 2.2 before and after 5 weeks of
degradation.
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